US20030152582A1 - CTL epitopes from EBV - Google Patents
CTL epitopes from EBV Download PDFInfo
- Publication number
- US20030152582A1 US20030152582A1 US10/356,829 US35682903A US2003152582A1 US 20030152582 A1 US20030152582 A1 US 20030152582A1 US 35682903 A US35682903 A US 35682903A US 2003152582 A1 US2003152582 A1 US 2003152582A1
- Authority
- US
- United States
- Prior art keywords
- seq
- ebv
- ctl
- epitope
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 196
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims abstract description 145
- 239000000427 antigen Substances 0.000 claims abstract description 86
- 108091007433 antigens Proteins 0.000 claims abstract description 86
- 102000036639 antigens Human genes 0.000 claims abstract description 86
- 238000000034 method Methods 0.000 claims abstract description 48
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 19
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 11
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 9
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 129
- 210000004027 cell Anatomy 0.000 claims description 106
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 74
- 101800001271 Surface protein Proteins 0.000 claims description 72
- 230000004044 response Effects 0.000 claims description 44
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 42
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 39
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 39
- 201000006747 infectious mononucleosis Diseases 0.000 claims description 33
- 241000700605 Viruses Species 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 32
- 229960005486 vaccine Drugs 0.000 claims description 30
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 23
- 208000007089 vaccinia Diseases 0.000 claims description 22
- 229940031626 subunit vaccine Drugs 0.000 claims description 16
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 208000017604 Hodgkin disease Diseases 0.000 claims description 12
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims description 9
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 230000000638 stimulation Effects 0.000 claims description 8
- 229960000814 tetanus toxoid Drugs 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- 241000607142 Salmonella Species 0.000 claims description 4
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims description 3
- 241000588832 Bordetella pertussis Species 0.000 claims description 2
- 241000991587 Enterovirus C Species 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 101150113776 LMP1 gene Proteins 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 101710192602 Latent membrane protein 1 Proteins 0.000 description 57
- 238000003556 assay Methods 0.000 description 37
- 239000012636 effector Substances 0.000 description 34
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 20
- 238000002649 immunization Methods 0.000 description 20
- 230000009089 cytolysis Effects 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 241000700618 Vaccinia virus Species 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 15
- 210000003719 b-lymphocyte Anatomy 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 15
- 230000009257 reactivity Effects 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 208000011691 Burkitt lymphomas Diseases 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 108700028369 Alleles Proteins 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 108010029714 A2-binding peptide Proteins 0.000 description 8
- 101710122227 Epstein-Barr nuclear antigen 1 Proteins 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 238000011830 transgenic mouse model Methods 0.000 description 8
- 238000007798 limiting dilution analysis Methods 0.000 description 7
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 101150013553 CD40 gene Proteins 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 101150089665 EBNA4 gene Proteins 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 101150097497 GPT1 gene Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000002784 cytotoxicity assay Methods 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- -1 t-butoxy carboxyl Chemical group 0.000 description 4
- 241000710929 Alphavirus Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- FOBUGKUBUJOWAD-IHPCNDPISA-N Leu-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FOBUGKUBUJOWAD-IHPCNDPISA-N 0.000 description 3
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 3
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 3
- 241000288960 Saguinus oedipus Species 0.000 description 3
- KHCSOLAHNLOXJR-BZSNNMDCSA-N Tyr-Leu-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHCSOLAHNLOXJR-BZSNNMDCSA-N 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229940023146 nucleic acid vaccine Drugs 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229960004854 viral vaccine Drugs 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- 108010011667 Ala-Phe-Ala Proteins 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 241000178270 Canarypox virus Species 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 235000019005 Digitaria californica Nutrition 0.000 description 2
- 241001115843 Digitaria californica Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QXDXIXFSFHUYAX-MNXVOIDGSA-N Glu-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O QXDXIXFSFHUYAX-MNXVOIDGSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- PWUMCBLVWPCKNO-MGHWNKPDSA-N Ile-Leu-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PWUMCBLVWPCKNO-MGHWNKPDSA-N 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- FAELBUXXFQLUAX-AJNGGQMLSA-N Leu-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C FAELBUXXFQLUAX-AJNGGQMLSA-N 0.000 description 2
- QQXJROOJCMIHIV-AVGNSLFASA-N Leu-Val-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O QQXJROOJCMIHIV-AVGNSLFASA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- LXUJDHOKVUYHRC-KKUMJFAQSA-N Phe-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=CC=C1)N LXUJDHOKVUYHRC-KKUMJFAQSA-N 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- PXYJUECTGMGIDT-WDSOQIARSA-N Trp-Arg-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 PXYJUECTGMGIDT-WDSOQIARSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 244000052637 human pathogen Species 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 241001515942 marmosets Species 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 108700043516 mouse H-2Kb Proteins 0.000 description 2
- 229940126578 oral vaccine Drugs 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 108010082406 peptide permease Proteins 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- CLCPDSJUXHDRGX-UHFFFAOYSA-N 6-(1,3-dihydroxyisobutyl)thymine Chemical compound CC1=C(CC(CO)CO)NC(=O)NC1=O CLCPDSJUXHDRGX-UHFFFAOYSA-N 0.000 description 1
- OQKYEMHWZYHWBL-UHFFFAOYSA-N 9h-fluoren-1-ylmethanol Chemical class C1C2=CC=CC=C2C2=C1C(CO)=CC=C2 OQKYEMHWZYHWBL-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- WQVYAWIMAWTGMW-ZLUOBGJFSA-N Ala-Asp-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N WQVYAWIMAWTGMW-ZLUOBGJFSA-N 0.000 description 1
- HJGZVLLLBJLXFC-LSJOCFKGSA-N Ala-His-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(O)=O HJGZVLLLBJLXFC-LSJOCFKGSA-N 0.000 description 1
- TZDNWXDLYFIFPT-BJDJZHNGSA-N Ala-Ile-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O TZDNWXDLYFIFPT-BJDJZHNGSA-N 0.000 description 1
- UWIQWPWWZUHBAO-ZLIFDBKOSA-N Ala-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)CC(C)C)C(O)=O)=CNC2=C1 UWIQWPWWZUHBAO-ZLIFDBKOSA-N 0.000 description 1
- RGQCNKIDEQJEBT-CQDKDKBSSA-N Ala-Leu-Tyr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 RGQCNKIDEQJEBT-CQDKDKBSSA-N 0.000 description 1
- XRUJOVRWNMBAAA-NHCYSSNCSA-N Ala-Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 XRUJOVRWNMBAAA-NHCYSSNCSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- VNFSAYFQLXPHPY-CIQUZCHMSA-N Ala-Thr-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNFSAYFQLXPHPY-CIQUZCHMSA-N 0.000 description 1
- YBZMTKUDWXZLIX-UWVGGRQHSA-N Arg-Leu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YBZMTKUDWXZLIX-UWVGGRQHSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101100216993 Bacillus subtilis (strain 168) aroD gene Proteins 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- WVLZTXGTNGHPBO-SRVKXCTJSA-N Cys-Leu-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O WVLZTXGTNGHPBO-SRVKXCTJSA-N 0.000 description 1
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 1
- ZXGDAZLSOSYSBA-IHRRRGAJSA-N Cys-Val-Phe Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ZXGDAZLSOSYSBA-IHRRRGAJSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 101150113929 EBNA2 gene Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- DXMPMSWUZVNBSG-QEJZJMRPSA-N Gln-Asn-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)N DXMPMSWUZVNBSG-QEJZJMRPSA-N 0.000 description 1
- XFAUJGNLHIGXET-AVGNSLFASA-N Gln-Leu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XFAUJGNLHIGXET-AVGNSLFASA-N 0.000 description 1
- MLSKFHLRFVGNLL-WDCWCFNPSA-N Gln-Leu-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MLSKFHLRFVGNLL-WDCWCFNPSA-N 0.000 description 1
- ILGFBUGLBSAQQB-GUBZILKMSA-N Glu-Glu-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ILGFBUGLBSAQQB-GUBZILKMSA-N 0.000 description 1
- CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
- DLISPGXMKZTWQG-IFFSRLJSSA-N Glu-Thr-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O DLISPGXMKZTWQG-IFFSRLJSSA-N 0.000 description 1
- AFWYPMDMDYCKMD-KBPBESRZSA-N Gly-Leu-Tyr Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AFWYPMDMDYCKMD-KBPBESRZSA-N 0.000 description 1
- FOKISINOENBSDM-WLTAIBSBSA-N Gly-Thr-Tyr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FOKISINOENBSDM-WLTAIBSBSA-N 0.000 description 1
- 239000004471 Glycine Chemical group 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 101710121925 Hemagglutinin glycoprotein Proteins 0.000 description 1
- DRKZDEFADVYTLU-AVGNSLFASA-N His-Val-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O DRKZDEFADVYTLU-AVGNSLFASA-N 0.000 description 1
- 101000986079 Homo sapiens HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- QIHJTGSVGIPHIW-QSFUFRPTSA-N Ile-Asn-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N QIHJTGSVGIPHIW-QSFUFRPTSA-N 0.000 description 1
- LBRCLQMZAHRTLV-ZKWXMUAHSA-N Ile-Gly-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LBRCLQMZAHRTLV-ZKWXMUAHSA-N 0.000 description 1
- TWPSALMCEHCIOY-YTFOTSKYSA-N Ile-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O)N TWPSALMCEHCIOY-YTFOTSKYSA-N 0.000 description 1
- UAELWXJFLZBKQS-WHOFXGATSA-N Ile-Phe-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(O)=O UAELWXJFLZBKQS-WHOFXGATSA-N 0.000 description 1
- IVXJIMGDOYRLQU-XUXIUFHCSA-N Ile-Pro-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O IVXJIMGDOYRLQU-XUXIUFHCSA-N 0.000 description 1
- APQYGMBHIVXFML-OSUNSFLBSA-N Ile-Val-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N APQYGMBHIVXFML-OSUNSFLBSA-N 0.000 description 1
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- QPRQGENIBFLVEB-BJDJZHNGSA-N Leu-Ala-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O QPRQGENIBFLVEB-BJDJZHNGSA-N 0.000 description 1
- WCTCIIAGNMFYAO-DCAQKATOSA-N Leu-Cys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O WCTCIIAGNMFYAO-DCAQKATOSA-N 0.000 description 1
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 1
- YSKSXVKQLLBVEX-SZMVWBNQSA-N Leu-Gln-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 YSKSXVKQLLBVEX-SZMVWBNQSA-N 0.000 description 1
- OMHLATXVNQSALM-FQUUOJAGSA-N Leu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(C)C)N OMHLATXVNQSALM-FQUUOJAGSA-N 0.000 description 1
- UBZGNBKMIJHOHL-BZSNNMDCSA-N Leu-Leu-Phe Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 UBZGNBKMIJHOHL-BZSNNMDCSA-N 0.000 description 1
- AUNMOHYWTAPQLA-XUXIUFHCSA-N Leu-Met-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AUNMOHYWTAPQLA-XUXIUFHCSA-N 0.000 description 1
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 1
- MAXILRZVORNXBE-PMVMPFDFSA-N Leu-Phe-Trp Chemical compound C([C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 MAXILRZVORNXBE-PMVMPFDFSA-N 0.000 description 1
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
- FPFOYSCDUWTZBF-IHPCNDPISA-N Leu-Trp-Leu Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H]([NH3+])CC(C)C)C(=O)N[C@@H](CC(C)C)C([O-])=O)=CNC2=C1 FPFOYSCDUWTZBF-IHPCNDPISA-N 0.000 description 1
- CGHXMODRYJISSK-NHCYSSNCSA-N Leu-Val-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O CGHXMODRYJISSK-NHCYSSNCSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- IRNSXVOWSXSULE-DCAQKATOSA-N Lys-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN IRNSXVOWSXSULE-DCAQKATOSA-N 0.000 description 1
- NTSPQIONFJUMJV-AVGNSLFASA-N Lys-Arg-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O NTSPQIONFJUMJV-AVGNSLFASA-N 0.000 description 1
- SQXZLVXQXWILKW-KKUMJFAQSA-N Lys-Ser-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQXZLVXQXWILKW-KKUMJFAQSA-N 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 1
- USBFEVBHEQBWDD-AVGNSLFASA-N Met-Leu-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O USBFEVBHEQBWDD-AVGNSLFASA-N 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methyl urea Chemical compound CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- BBDSZDHUCPSYAC-QEJZJMRPSA-N Phe-Ala-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BBDSZDHUCPSYAC-QEJZJMRPSA-N 0.000 description 1
- KJJROSNFBRWPHS-JYJNAYRXSA-N Phe-Glu-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KJJROSNFBRWPHS-JYJNAYRXSA-N 0.000 description 1
- VZFPYFRVHMSSNA-JURCDPSOSA-N Phe-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=CC=C1 VZFPYFRVHMSSNA-JURCDPSOSA-N 0.000 description 1
- KPEIBEPEUAZWNS-ULQDDVLXSA-N Phe-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 KPEIBEPEUAZWNS-ULQDDVLXSA-N 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- BODDREDDDRZUCF-QTKMDUPCSA-N Pro-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]2CCCN2)O BODDREDDDRZUCF-QTKMDUPCSA-N 0.000 description 1
- BXHRXLMCYSZSIY-STECZYCISA-N Pro-Tyr-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1)C(O)=O BXHRXLMCYSZSIY-STECZYCISA-N 0.000 description 1
- 241000282335 Procyon Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 229940124857 Salmonella typhi vaccine Drugs 0.000 description 1
- IXZHZUGGKLRHJD-DCAQKATOSA-N Ser-Leu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IXZHZUGGKLRHJD-DCAQKATOSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- PRNGXSILMXSWQQ-OEAJRASXSA-N Thr-Leu-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PRNGXSILMXSWQQ-OEAJRASXSA-N 0.000 description 1
- NWECYMJLJGCBOD-UNQGMJICSA-N Thr-Phe-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O NWECYMJLJGCBOD-UNQGMJICSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- AVYVKJMBNLPWRX-WFBYXXMGSA-N Trp-Ala-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 AVYVKJMBNLPWRX-WFBYXXMGSA-N 0.000 description 1
- MDDYTWOFHZFABW-SZMVWBNQSA-N Trp-Gln-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 MDDYTWOFHZFABW-SZMVWBNQSA-N 0.000 description 1
- RPVDDQYNBOVWLR-HOCLYGCPSA-N Trp-Gly-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O RPVDDQYNBOVWLR-HOCLYGCPSA-N 0.000 description 1
- CXPJPTFWKXNDKV-NUTKFTJISA-N Trp-Leu-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 CXPJPTFWKXNDKV-NUTKFTJISA-N 0.000 description 1
- CCZXBOFIBYQLEV-IHPCNDPISA-N Trp-Leu-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(O)=O CCZXBOFIBYQLEV-IHPCNDPISA-N 0.000 description 1
- HTGJDTPQYFMKNC-VFAJRCTISA-N Trp-Thr-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)O)=CNC2=C1 HTGJDTPQYFMKNC-VFAJRCTISA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 description 1
- FASACHWGQBNSRO-ZEWNOJEFSA-N Tyr-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CC=C(C=C2)O)N FASACHWGQBNSRO-ZEWNOJEFSA-N 0.000 description 1
- SCZJKZLFSSPJDP-ACRUOGEOSA-N Tyr-Phe-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O SCZJKZLFSSPJDP-ACRUOGEOSA-N 0.000 description 1
- 108010064997 VPY tripeptide Proteins 0.000 description 1
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 description 1
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 1
- ZZGPVSZDZQRJQY-ULQDDVLXSA-N Val-Leu-Phe Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O ZZGPVSZDZQRJQY-ULQDDVLXSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 1
- 101150042732 aroC gene Proteins 0.000 description 1
- 101150102858 aroD gene Proteins 0.000 description 1
- 101150040872 aroE gene Proteins 0.000 description 1
- 101150108612 aroQ gene Proteins 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 101150018266 degP gene Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ISLJZDYAPAUORR-UHFFFAOYSA-N ethyl n-[2-[(5-nitrothiophene-2-carbonyl)amino]thiophene-3-carbonyl]carbamate Chemical compound C1=CSC(NC(=O)C=2SC(=CC=2)[N+]([O-])=O)=C1C(=O)NC(=O)OCC ISLJZDYAPAUORR-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 101150007310 htrA gene Proteins 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940023832 live vector-vaccine Drugs 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 235000008954 quail grass Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to methods of treating or preventing EBV infections.
- the present invention also relates to cytotoxic T-cell (CTL) epitopes within Epstein-Barr virus (EBV) structural and latent antigens, and to subunit vaccines and nucleic acid vaccines which include these epitopes.
- CTL cytotoxic T-cell
- EBV Epstein-Barr virus
- PTLD Post-transplant lymphoproliferative disease
- Histological analysis of PTLD shows a quite complex clonal diversity ranging from polymorphic B lymphocyte hyperplasia to malignant monoclonal lymphoma. This range of pathology encompasses the collective term PTLD while the lymphomas are frequently referred to as immunoblastic lymphomas(IL).
- IL immunoblastic lymphomas
- EBV-infected B cells are normally restricted in their growth in vitro and in vivo by virus-specific cytotoxic T cells (CTLs) which recognise epitopes included within the EBV latent proteins (see below) (48). Immunosuppression inhibits these specific CTL and results in an expansion of the pool of EBV-infected B cells and the emergence of the clinical problems associated with PTLD. It is known that the individuals at greatest risk of PTLD are EBV seronegative recipients who receive a transplant from a seropositive donor (Crawford and Thomas, 1993). Immunisation of EBV seronegative graft recipients prior to engraftment will greatly reduce the risk of PTLD.
- CTLs virus-specific cytotoxic T cells
- EBV nuclear antigen 1 EBNA1
- LMP1 latent membrane protein 1
- results obtained by the present inventors indicate that CTL epitopes within EBV structural and latent proteins may be effective in providing antiviral immunity against EBV infection.
- the present inventors have analysed the latent antigen LMP1 sequence, using peptide stablization assays, and found that this antigen includes potential CTL epitopes.
- LMP1 sequence peptide stablization assays
- both polyclonal and clonal CTLs from HLA A2-positive donors showed strong reactivity against target cells expressing the LMP1 antigen.
- lymphoblastoid cell lines (LCL) expressing different HLA A2 supertypes were efficiently recognized by these CTLs, a result that has important implications for the design of an anti-viral vaccine aimed at protecting different ethnic populations.
- CTLs from acute infectious mononucleosis (IM) patients display strong reactivity against the EBV structural antigens gp85 and gp350.
- specific CTL epitopes within EBV structural antigens gp85 and gp350 have been identified for the first time.
- prior immunisation of HLA A2/K b transgenic mice with these gp350 and gp85 CTL epitopes induced a strong epitope-specific CTL response and afforded protection against gp85- or gp350-expressing vaccinia virus challenge.
- the present invention provides a cytotoxic Epstein-Barr virus (EBV) T-cell epitope, the epitope being derived from an EBV structural antigen.
- EBV Epstein-Barr virus
- the EBV structural antigen is gp85 or gp350.
- the present invention provides a cytotoxic Epstein-Barr virus T-cell epitope, the epitope being selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), YLQQNWWTL (SEQ ID NO: 6), LLLALLFWL (SEQ ID NO: 2), LLVDLLWLL (SEQ ID NO: 3), LLLIALWNL (SEQ ID NO: 4), WLLLFLAIL (SEQ ID NO: 5), TLLVDLLWL (SEQ ID NO: 7), LLWLLLFLA (SEQ ID NO: 8), ILLIIALYL (SEQ ID NO: 9), VLFIFGCLL (SEQ ID NO: 10), RLGATIWQL (SEQ ID NO: 11), ILYFIAFAL (SEQ ID NO: 15), SLVIVTTFV (SEQ ID NO: 17), L
- the present invention provides a subunit vaccine including a cytotoxic Epstein-Barr virus (EBV) T-cell epitope according to the first aspect of the present invention.
- EBV Epstein-Barr virus
- the subunit vaccine includes at least one T-cell epitope selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), YLQQNWWTL (SEQ ID NO: 6), LLLALLFWL (SEQ ID NO: 2), LLVDLLWLL (SEQ ID NO: 3), LLLIALWNL (SEQ ID NO: 4), WLLLFLAIL (SEQ ID NO: 5), TLLVDLLWL (SEQ ID NO: 7), LLWLLLFLA (SEQ ID NO: 8), ILLIIALYL (SEQ ID NO: 9), VLFIFGCLL (SEQ ID NO: 10), RLGATIWQL (SEQ ID NO: 11), ILYFIAFAL (SEQ ID NO: 15), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20),
- the epitope is selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YLQQNWWTL (SEQ ID NO: 6), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), and VLQWASLAV (SEQ ID NO: 27).
- the subunit vaccine includes one or more additional cytotoxic EBV T-cell epitopes.
- the additional cytotoxic EBV T-cell epitope(s) may be selected from those described in WO 97/45444, the entire contents of which are incorporated herein by reference.
- the vaccine includes a water-in-oil formulation. It is further preferred that the vaccine includes at least one antigen to which the individual will mount an anamnestic response in addition to the at least one cytotoxic T-cell epitope.
- the at least one antigen is preferably selected from the group consisting of tetanus toxoid. diphtheria toxoid, Bordetella pertussis antigens, poliovirus antigens, purified protein derivative (PPD), gp350 protein (Thorley-Lawson, D. A. and Poodry, G. A. (1982). Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J. Virol. 43, 730-736), helper epitopes and combinations thereof and is preferably tetanus toxoid.
- the water-in-oil formulation is Montanide ISA 720. Additional information regarding this formulation can be found in WO 95/24926, the disclosure of which is incorporated herein by cross reference.
- the subunit vaccine may also be formulated using ISCOMs. Further information regarding ISCOMs can be found in Australian Patent Nos. 558258, 590904, 632067, 589915, the disclosures of which are included herein by cross reference.
- the present invention provides an isolated nucleic acid sequence encoding a cytotoxic Epstein-Barr virus (EBV) T-cell epitope according to the first aspect of the present invention.
- EBV Epstein-Barr virus
- the isolated nucleic acid sequence encodes at least one of the cytotoxic T-cell epitopes selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), YLQQNWWTL (SEQ ID NO: 6), LLLALLFWL (SEQ ID NO: 2), LLVDLLWLL (SEQ ID NO: 3), LLLIALWNL (SEQ ID NO: 4), WLLLFLAIL (SEQ ID NO: 5), TLLVDLLWL (SEQ ID NO: 7), LLWLLLFLA (SEQ ID NO: 8), ILLIIALYL (SEQ ID NO: 9), VLFIFGCLL (SEQ ID NO: 10), RLGATIWQL (SEQ ID NO: 11), ILYFIAFAL (SEQ ID NO: 15), SLVIVTTFV (SEQ ID NO: 17), LMIIP
- nucleic acid sequence can be delivered as naked nucleic acid or using a suitable viral or bacterial vectors.
- Suitable bacterial vectors include the bacteria Salmonella spp.
- Suitable viral vectors include, for example, retroviral vectors, adenoviral vectors and vaccinia vectors.
- An example of a suitable vaccinia vector is a modified Vaccinia Ankara vector.
- alphavirus vectors have become widely used in basic research to study thestructure and function of proteins and for protein production purposes. Development of a variety of vectors has made it possible to deliver foreignsequences as naked RNA or DNA, or as suicide virus particles produced using helper vector strategies. Preliminary reports also suggest that these vectors may be useful for in vivo applications where transient, high-level protein expression is desired, such as recombinant vaccines. The initial studies have already shown that alphavirus vaccines can induce strong humoral and cellular immune responses with good immunological memory and protective effects.
- Recombinant pox viruses have been generated for vaccination against heterologous pathogens. Amongst these, the following are notable examples.
- a fowlpox-based recombinant expressing the Newcastle disease virus fusion and hemagglutinin glycoproteins has been shown to protect commercial broiler chickens for their lifetime when the vaccine was administered at 1 day of age, even in the presence of maternal immunity against either the Newcastle disease virus or the pox vector.
- Recombinants of canarypox virus which is restricted for replication to avian species, have provided protection against rabies virus challenge in cats and dogs, against canine distemper virus, feline leukemia virus, and equine influenza virus disease. In humans, canarypox virus-based recombinants expressing antigens from rabies virus.
- a further derivative prepared by introducing a deletion in htrA (which encodes a heat-shock protein that also has activity as a serine protease in CVD 908 resulted in CVD 908-htrA.
- CVD 908-htrA appears very attractive as a live oral vaccine candidate. Both CVD 908 and CVD 908-htrA are useful as live vector vaccines to deliver foreign antigens to the immune system.
- the isolated nucleic acid sequences may be in the form of nucleic acid vaccines. Further information regarding nucleic acid vaccines can be found in WO 96/03144 and in Suhrbier A (1997), Multi-epitope DNA vaccines, Immunol Cell Biol 75(4):402-408 the disclosures of which are incorporated herein by cross reference.
- the present invention provides an isolated polypeptide, the polypeptide including at least one epitope according to the first or second aspects of the present invention.
- the vaccines of the present invention may be used prophylactically or therapeutically.
- the CTL epitopes of the present invention may be synthesised using techniques well known to those skilled in this field.
- the CTL epitopes may be synthesised using solution synthesis or solid phase synthesis as described, for example, in Chapter 9 entitled “Peptide Synthesis” by Atherton and Sheppard which is included in a publication entitled “Synthetic Vaccines” edited by Nicholson and published by Blackwell Scientific Publications.
- a solid phase support is utilised which may be polystyrene gel beads wherein the polystyrene may be cross-linked with a small proportion of divinylbenzene (e.g.
- polystyrene may be functionalised with chloromethyl or anionomethyl groups.
- cross-linked and functionalised polydimethyl-acrylamide gel is used which may be highly solvated and swollen by DMF and other dipolar aprolic solvents.
- Other supports can be utilised based on polyethylene glycol which is usually grafted or otherwise attached to the surface of inert polystyrene beads. In a preferred form, use may be made of commercial solid supports or resins which are selected from PAL-PEG, PAK-PEG, KA, KR or TGR.
- reversible blocking groups which have the dual function of masking unwanted reactivity in the a-amino, carboxy or side chain functional groups and of destroying the dipolar character of amino acids and peptides which render them inactive.
- Such functional groups can be selected from t-butyl esters of the structure RCO—OCMe 3 —CO—NHR which are known as t-butoxy carboxyl or ROC derivatives.
- Use may also be made of the corresponding benzyl esters having the structure RCO—OCH 2 —C 6 H 5 and urethanes having the structure C 6 H 5 CH 2 O CO—NHR which are known as the benzyloxycarbonyl or Z-derivatives.
- Use may also be made of derivatives of fluorenyl methanol and especially the fluorenyl-methoxy carbonyl or Fmoc group.
- Each of these types of protecting group is capable of independent cleavage in the presence of one other so that frequent use is made, for example, of BOC-benzyl and Fmoc-tertiary butyl protection strategies.
- a condensing agent to link the amino and carboxy groups of protected amino acids or peptides. This may be done by activating the carboxy group so that it reacts spontaneously with a free primary or secondary amine. Activated esters such as those derived from p-nitrophenol and pentafluorophenyl may be used for this purpose. Their reactivity may be increased by addition of catalysts such as 1-hydroxybenzotriazole. Esters of triazine DHBT (as discussed on page 215-216 of the abovementioned Nicholson reference) also may be used. Other acylating species are formed in situ by treatment of the carboxylic acid (i.e.
- N ⁇ -protected amino acid or peptide with a condensing reagent and are reacted immediately with the amino component (the carboxy or C-protected amino acid or peptide).
- Dicyclohexylcarbodiimide, the BOP reagent (referred to on page 216 of the Nicholson reference), O'Benzotriazole-N,N, N′N′-tetra methyl-uronium hexaflurophosphate (HBTU) and its analogous tetrafluroborate are frequently used condensing agents.
- HBTU O'Benzotriazole-N,N, N′N′-tetra methyl-uronium hexaflurophosphate
- HBTU O'Benzotriazole-N,N, N′N′-tetra methyl-uronium hexaflurophosphate
- HBTU O'Benzotriazole-N,N, N′N′-tetra methyl-uronium
- the attachment of the first amino acid to the solid phase support may be carried out using BOC-amino acids in any suitable manner.
- BOC amino acids are attached to chloromethyl resin by warming the triethyl ammonium salts with the resin.
- Fmoc-amino acids may be coupled to the p-alkoxybenzyl alcohol resin in similar manner.
- use may be made of various linkage agents or “handles” to join the first amino acid to the resin.
- p-hydroxymethyl phenylactic acid linked to aminomethyl polystyrene may be used for this purpose.
- the LMP1, gp85 and gp350 epitopes and vaccines of the present invention can be used to treat and to protect against EBV. Further, given the possible greater involvement of EBV infection in immunocompromised individuals, the present invention may have particular application in the treatment and protection of individuals having decreased immune function, eg transplant patients. Importantly, the present inventors have found that EBV transformed lymphoblastoid cell lines expressing different HLA A2 supertypes are efficiently recognised by LMP1-specific CTL clones. This highlights the potential for the design of an antiviral vaccine aimed at treating and protecting different ethnic populations.
- the present invention provides a method of preparing a composition for use in inducing CTLs in a subject, the method including admixing at least one epitope according to the first or second aspects of the present invention with at least one pharmaceutical acceptable carrier, diluent or excipient.
- the present invention provides a method of reducing the risk of EBV infection in a subject which method includes administering to the subject an effective amount of:
- the present invention provides a method of treating or preventing nasopharyngeal carcinoma or Hodgkin's disease in a subject which method includes administering to the subject an effective amount of at least one CTL epitope derived from an EBV structural or latent antigen.
- an effective amount we mean a quantity of the epitope which is sufficient to induce or amplify a CTL response against an EBV antigen.
- the EBV structural antigen is gp85 or gp350 and the latent antigen is LMP1 or LMP2.
- the CTL epitope is an epitope as defined in the second aspect of the present invention.
- the present inventors have also made the surprising finding that NPC cells which are recognised by CTL clones are subject to CTL lysis. This finding has important implications for the design of vaccines to control NPC tumours in vivo.
- the present invention provides a method of treating or preventing growth of NPC or HD cells in a subject in need thereof which method includes administering to the subject at least one CTL epitope derived from an EBV structural or latent antigen.
- the EBV CTL epitopes are derived from the gp85 or gp350 antigens.
- the EBV CTL epitopes are derived from the LMP1 or LMP2 antigens.
- the CTL epitopes are derived from the LMP1 antigen.
- the present invention provides a method of treating or preventing the growth of NPC or HD cells in a first subject which method includes transferring to the subject EBV-specific CTLs which recognise NPC or HD cells.
- the EBV-specific CTLs are obtained from NPC patients by in vitro stimulation of CTLs by exposure to EBV CTL epitopes.
- the EBV-specific CTLs may be obtained from a second subject, wherein the second subject is infected with EBV but does not have NPC.
- the EBV-specific CTLs are LMP1 and/or LMP2-specific CTLs.
- the present invention provides a method of reducing the risk of infectious mononucleosis or post transplantation lymphoproliferative disease in a subject which method includes administering to the subject an effective amount of:
- FIG. 1 MHC stablization analysis on T2 cells using potential HLA A2 binding peptides within LMP1.
- T2 cells were initially incubated with 200 ⁇ l of each of the peptides (200 ⁇ g/ml) for 14-16 h at 26° C. followed by incubation at 37° C. for 2-3 h.
- HLA A2 expression on these cells was analysed by FACS using the BB7.2 antibody.
- the dotted line indicates the background mean fluorescence intensity for HLA A2 on T2 cells without any peptide.
- the LMP1 peptides showing significant stablization of HLA A2 molecules on T2 cells are indicated by arrows.
- FIG. 2 Recognition of LMP1 peptides by polyclonal CTLs from an HLA A2-positive donor SB.
- PBMC from donor SB were co-cultivated for seven days with irradiated T2 cells sensitized with synthetic peptides (indicated on the Y-axis). On day 10, these cells were used as polyclonal effectors in a standard 51 Cr-release assay against peptide-sensitized (1 ⁇ g/ml) autologous PHA blasts. An effector:target ratio of 20:1 was used in the assay. Data from one representative experiment out of three is shown. Results are expressed as percent specific lysis.
- FIG. 3 Specific lysis by an EBV-specific CTL clone (SB7) from donor SB of autologous LCLs and autologous CD40 B cells infected with Vacc.EBNA1, 2, 3, 4, 5, 6, LMP1, LMP2A and Vacc.TK ⁇ (panel A).
- Vacc.TK ⁇ was used as a control recombinant vaccinia.
- LMP1-and HLA A2-positive BL cell lines BJAB.MTLM6 or Mutu cl.59
- LMP1-negative, HLA A2-positive BL cell lines BJAB.gpt1 and Mutu cl.216
- FIG. 4 CTLp frequencies for the LMP1 epitopes YLQQNWWTL (SEQ ID NO: 6) (A) and YLLEMLWRL (SEQ ID NO:1) (B) in HLA A2-positive donor are shown.
- the frequencies of CTLp for peptides YLQQNWWTL (SEQ ID NO: 6) (A) and YLLEMLWRL (SEQ ID NO: 1) (B) were estimated in peripheral blood lymphocytes from donor SB.
- PBMC from this donor was stimulated with peptides sensitized PBMC as described in the “Materials and Methods” section. Reciprocal values of responder frequencies (f 1 ) are indicated. The shaded areas indicate 95% confidence limits.
- FIG. 5 CTL recognition of LCLs expressing different supertypes of HLA A2 by the SB7 CTL clone. All LCLs used in this assay were transformed with the B95.8 EBV isolate. The HLA A2 subtyping for each LCL was assigned by the 12th Histocompatability workshop. An effector:target ratio of 4:1 was used in both the assay. Results are expressed as percent specific lysis. Data from one representative experiment out of four is shown.
- FIG. 6 Effect of variant LMP1 peptides on the HLA A2 binding (panel A) and CTL recognition (panel B).
- HLA A2 binding analysis on T2 cells were initially incubated with 200 ⁇ l of each of the peptides (200 ⁇ g/ml) for 14-16 h at 26° C. followed by incubation at 37° C. for 2-3 h.
- HLA A2 expression on these cells was analysed by FACS using BB7.2 antibody (panel A).
- the dotted line indicates the background mean fluorescence intensity for HLA A2 on T2 cells without any peptide.
- CTL recognition of the variant and prototypic HLA A2-restricted LMP1 epitope For CTL recognition of the variant and prototypic HLA A2-restricted LMP1 epitope.
- FIG. 7 CTL recognition of NPC cells and LCLs by EBV-specific HLA A11-restricted CTL clones CM9 (a & c) and CM29 (b & d).
- Vacc.EBNA4, Vacc.TK infected or peptide sensitized C15NPC cells (a & b) were exposed to CTL clones at different effector to target ratios and the level of CTL lysis was compared to a type 2 LGLs (CM/Ag876 LCL).
- As a positive control target cells were either presensitized with IVTDFSVIK peptide (a & c), or AVFDRKSDAK peptide (b & d). The results were expressed as per cent specific lysis.
- FIG. 8 MHC stabilization analysis on T2 cells using potential HLA A2 binding peptides within gp85 (panel A) and gp350 (panel B).
- T2 cells were initially incubated with 200 Tl of each of the peptides (200 Tg/ml) for 14-16 h at 26° C. followed by incubation at 37° C. for 2-3 h.
- HLA A2 expression on these cells was analysed by FACS using the BB7.2 antibody.
- the dotted line indicates the background mean fluorescence intensity for HLA A2 on T2 cells without any peptide.
- the gp85 and gp350 peptides showing significant stabilization of HLA A2 molecules on T2 cells are indicated by arrows.
- FIG. 9 gp85 and gp350-specific ex vivo cytotoxic T cell activity in peripheral blood lymphocytes from IM donors.
- Panel A, B & C shows ex vivo CTL lysis of peptide-sensitized (1 ⁇ g/ml) PHA blasts at two different effector:target (E/T) ratios.
- E/T effector:target
- Panel D shows ex vivo CTL lysis by peripheral blood lymphocytes from patient LP of target cells infected with recombinant vaccinia encoding either gp85 (Vacc.gp85) or gp350 (Vacc.350) by.
- Vacc.TK ⁇ and Vacc.EBNA2 were used as control in the assay.
- FIG. 10 Recognition of gp85 and gp350 peptides by polyclonal CTLs from an HLA A2-positive IM recovered (36 months post IM) individual.
- PBMC peripheral blood mononuclear cells
- T2 cells irradiated T2 cells sensitized with synthetic peptides (indicated on the Y-axis).
- synthetic peptides indicated on the Y-axis.
- Individual peptide stimulated CTL effectors used in this experiments are indicated in the figure. Data from one representative experiment out of three is shown. Results are expressed as percent specific lysis.
- FIG. 11 Immunization of HLA A2/K b mice with gp85 and gp350 CTL epitopes induces strong CTL response. Animals were twice immunized (at a 14 day interval) subcutaneously with individual CTL epitope with Tetanus Toxoid as a source of help. Four weeks following peptide immunization, animals were assessed for gp350- and gp85-specific CTL response.
- Panel A, B & C shows CTL activity in splenocytes from two mice immunized with VLQWASLAV (SEQ ID NO: 27) (gp350), TLFIGSHVV (SEQ ID NO: 24) (gp85) and SLVIVTTFV (SEQ ID NO: 17) (gp85) respectively.
- CTL lysis of target cells sensitized with peptide epitopes are shown as filled symbols, while lysis of unsensitized target cells is shown as empty symbols.
- Panel D shows CTL activity in pooled inguinal lymphnodes from mice immunised with peptide VLQWASLAV (SEQ ID NO: 27) ( ⁇ , ⁇ ), SLVIVTTFV (SEQ ID NO: 17) ( ⁇ , ⁇ ) and TLFIGSHVV (SEQ ID NO: 24) ( ⁇ , ⁇ ). CTL activity was tested on day 6 using a standard 51Cr-release assay.
- FIG. 12 Prior immunisation of HLA A2/Kb mice with gp85 or gp350 CTL epitopes affords protection against recombinant vaccinia virus challenge.
- X-axis shows peptides used for immunization, while Y-axis shows Mean+/ ⁇ SE vaccinia virus titre in naive and peptide immunized mice. Recombinant vaccinia virus used for challenge in these animals is shown in each panel of the figure.
- LCLs were established from sero-positive donors by exogenous virus transformation of peripheral B cells using the B95.8 (Type 1) or Ag876 (Type 2) virus isolates.
- LCLs transformed with the B95.8 isolate and expressing different HLA A2 supertypes were also used in this study (12th Histocompatability workshop cell panel; EACC).
- the peptide transporter (TAP)-negative B ⁇ T hybrid cell line 174 ⁇ CEM.T2 (referred to as T2) (22) were used for peptide stablization assays.
- CD40 B cells All cell lines were routinely maintained in RPMI 1640 containing 2 mM glutamine, 100 IU/ml penicillin and 100 ug/ml streptomycin plus 10% foetal calf serum (FCS) (growth medium). Long-term cultures of EBV-negative normal B cell blasts were established as previously described using the CD40 system (referred to as CD40 B cells) (12).
- BL cell lines BJAB.gpt1, BJAB.MTLM6, MUTU cl.59 and MUTU cl.216 were used in this study. These were derived from patients with non-endemic or endemic BL. BJAB.MTLM6 and MUTU cl.59 have previously been shown to express LMP1, while BJAB.gpt1 and MUTU cl.216 are negative for LMP1 (5,27). These BL cell lines were routinely maintained in growth medium.
- PHA blasts To generate phytohaemagglutinin (PHA) blasts, peripheral blood mononuclear (PBMC) cells were stimulated with PHA (Commonwealth Serum Laboratories, Melbourne) and after 3 days, growth medium containing MLA 144 supernatant and rIL-2 was added (2). PHA blasts were propagated with bi-weekly replacement of IL-2 and MLA supernatant (no further PHA added) for up to 6 weeks.
- PHA phytohaemagglutinin
- oligonucleotide primers flanking the DNA region encoding the LMP1 epitope were selected for PCR amplification.
- the resulting PCR products were purified using QIAquick spin columns (Qiagen Inc. Chatsworth, Calif.) and sequenced in both directions using a PRISM ready reaction dyedeoxy terminator cycle sequencing kit (Applied Biosystems Inc., Foster City, Calif.) following the manufacturer's protocol.
- Peptides synthesized by the Merrifield solid phase method (16) were purchased from Chiron Mimotopes (Melbourne, Australia). dissolved in dimethyl sulphoxide and diluted in serum-free RPMI 1640 medium for use in standard CTL assays.
- PBMC from HLA A2-positive donors were co-cultivated for seven days with the irradiated (8,000 rads) T2 cells sensitized with synthetic peptides. On day 7, these lymphocytes were restimulated with peptide-sensitized T2 cells. After 10 days of culture in growth medium, the cells were used as polyclonal effectors in a standard 51 Cr-release assay against peptide-sensitized autologous PHA blasts.
- PBMC peripheral blood mononuclear cells
- peptide sensitized autologous lymphocytes responder to stimulator ratio of 4:1
- 2 ml culture wells Lobro
- CTL clones generated by seeding in 0.35% agarose, were established and maintained in growth medium containing highly purified recombinant human IL-2 from E. coli (16), restimulating twice weekly with autologous LCLs.
- CTL clones were screened on a panel of recombinant vaccinia-infected autologous CD40 B cells to confirm the antigen specificity (see below).
- Recombinant vaccinia constructs encoding EBV latent antigens and a vaccinia virus construct made by insertion of the pSC11 vector alone and negative for thymidine kinase have been previously described (6.11).
- CD40 B cells were infected with recombinant vaccinia virus at a multiplicity of infection (MOI) of 10:1 for 1 h at 37° C. as described earlier (6.11). After overnight infection, cells were washed with growth medium and processed for CTL assays or for immunoblotting to assess the expression of recombinant EBV antigens (12).
- Target cells were either infected with recombinant vaccinia viruses or pre-sensitized with synthetic peptide epitopes (wild-type or variant) and then incubated with 51 Cr for 90 min. Following incubation, these cells were washed in growth medium and used as targets in a standard 5 h 51 Cr-release assay (16).
- monoclonal antibodies MoAb
- W6/32 W6/32
- L243 class II
- PBMC from HLA A2-positive donors were distributed in graded numbers (two fold dilutions) from 6.25 ⁇ 10 3 to 5 ⁇ 10 4 cells per well in round-bottomed microtiter plates. Approximately 5 ⁇ 10 4 K-irradiated (2,000 rads) peptide sensitized (1 ⁇ g/ml) auologous PBMC were added to give a total volume of 100 ⁇ l. Twenty-four replicates were used at each concentration in each experiment. Cultures were fed on days 4 and 7 with 50 ⁇ l of medium supplemented with 20U of rIL-2 and 30% (vol/vol) supernatant from MLA-144 cultures.
- each CTL microculture was split into two replicates and used as effectors in a standard 5 h 51 Cr-release assay against autologous PHA blasts precoated with an LMP1 peptide or left uncoated.
- Wells were scored as positive when the percent specific chromium release for peptide-sensitized target cells exceeded the mean release from untreated control wells by 3 SDs.
- LDA was performed by the method of maximum likelihood estimation (4). Data from all experiments were compatible with the hypothesis of single-hit kinetics (P>0.4) and precursor estimates are given with 95% confidence limits.
- HLA A2-restricted epitopes within LMP1. The amino acid sequence was analyzed by a computer program designed to predict HLA-binding peptides, based on an estimation of the half-time disassociation of the HLA-peptide complex (http://bimas.dcrt.nih.gov/molbio/hla_bind/index.html) (18). A total of 11 peptides with an estimated half-time disassociation score of >400 were selected (Table 1). These peptides were then tested for HLA A2 binding efficiency using HLA A2-positive T2 cells. Representative data from a series of experiments is presented in FIG. 1. This analysis showed that six peptides significantly increased the expression of HLA A2 on T2 cells suggesting that these peptides bind to this allele.
- LMP1 includes sequences which can bind HLA A2 molecules and are therefore potential targets for virus-specific CTLs.
- PBMC from two HLA A2-positive EBV immune donors SB and AS were stimulated with T2 cells sensitized with each of the HLA A2-binding peptides from LMP1. On day 10, these effector cells were tested against peptide-sensitized autologous PHA blasts.
- Represtative data from polyclonal CTLs from donor SB are presented in FIG. 2.
- YLQQNWWTL SEQ ID NO: 6
- YLLEMLWRL SEQ ID NO: 1
- virus-specific CTL clones were generated using initial stimulation with peptide sensitized autologous PBMC followed by continous restimulation with irradiated autologous LCLs. Proliferating clones were screened for peptide recognition using the rapid visual assay for CTL specificity (2) and one clone, SB7, clearly recognized the YLLEMLWRL (SEQ ID NO: 1) peptide. No CTL clones specific for YLQQNWWTL (SEQ ID NO: 6) were isolated using this procedure.
- CTLp CTL precursors
- HLA A2-positive and TAP-negative T2 cells were also recognized by this clone suggesting that the YLLEMLWRL (SEQ ID NO: 1) epitope is endogenously processed through a TAP-independent pathway (FIG. 5).
- tumour cells were either infected with recombinant vaccinia encoding EBNA4 (Vacc.EBNA4) or presensitized with synthetic peptide epitopes.
- FIG. 7 illustrates the results from an experiment in which recombinant vaccinia-infected NPC cells (C15) were compared with HLA-matched type 2 LCLs infected with Vacc.EBNA4. Following exposure to EBNA4-specific CTLs, Vacc.EBNA4-infected or peptide sensitized NPC cells were efficiently recognised by both CM19 and CM29 CTL clones.
- NPC cells are able to transport sufficient levels of peptides into the ER by TAP-dependent mechanism and can efficiently transport MHC-peptide complexes from the ER to the surface of the cell.
- NPC normal antigen processing function in NPC cells has significant implications for vaccines designed to control these tumours in vivo. Earlier studies have demonstrated that the latent gene expression in NPC is often limited to EBNA1 and the transmembrane proteins, LMP1 and LMP2 (29).
- EBNA1 is not recognized by EBV-specific CTLs, there is an increasing emphasis on designing strategies to control NPC around epitopes known to be included within LMP1 (6,17).
- LMP epitopes will be processed efficiently by NPC cells.
- An effective approach to control NPC cells in vivo may be to amplify LMP-specific CTL responses in these patients. This might be achieved by two different procedures. Firstly, NPC patients might be immunised with synthetic peptides which include CTL epitopes from LMP1 and/or LMP2. Alternatively. LMP1 and LMP2-specific CTLs from HLA matched healthy virus carriers may be adoptively transferred into NPC patients in a manner analogous to that used to successfully treat EBV-associated polyclonal lymphomas in bone marrow transplant recipients (30).
- the CTL response characterized in the present report is of interest not only because it is directed against a viral antigen constitutively expressed in many EBV-associated malignancies (HD and NPC) but also because the HLA A2 allele is common in virtually all human populations (13). More importantly, EBV transformed LCLs expressing all the major HLA A2 supertypes were efficiently recognized by the LMP1-specific CTL clone, a result that has important implications for anti-viral vaccine design aimed at protect different ethnic populations. It is important to mention here that the CTL, response to the LMP1 epitope in healthy seropositive individuals constitutes a minor component of the virus-specific CTL response and very low levels of CTL precursors are seen for this epitope. It may nevertheless be possible to amplify this component by vaccination with the relevant peptide or with adoptive transfer of in vitro activated LMP1-specific CTLs. Such approaches may be of use in the control of HD and NPC.
- IM patients identified on clinical grounds and by heterophile antibody positivity, were bled during the first 5-10 days of illness and, in two cases, on a second occasion 24-36 months after the resolution of symptoms. These patients were HLA typed for the HLA A2 allele by serotyping in microcytotoxicity and by genotyping. Three patients (SB, LP and MG) were identified as HLA A2-positive patients and this was subsequently confirmed by FACS analysis using an HLA A2-specific monoclonal antibody (ATCC).
- HLA A2-specific monoclonal antibody ATCC
- EBV-transformed lymphoblastoid cell lines were established from a panel of IM and healthy EBV-seropositive donors by exogenous virus transformation of peripheral B cells using type 1 (B95.8) or type 2 (Ag876) EBV isolates (16), and were routinely maintained in RPMI 1640 containing 2 mM glutamine, 100 IU/ml penicillin and 100 ug/ml streptomycin plus 10% foetal calf serum (FCS) (growth medium).
- FCS foetal calf serum
- T2 peptide transporter-negative B ⁇ T hybrid cell line 174 ⁇ CEM.T2
- PHA phytohaemagglutinin
- Acute IM PBMC effectors for use in ex vivo cytotoxicity assays were resuspended in growth medium supplemented with recombinant IL2 and used directly in a cytotoxicity assay (see below).
- PBMCs from HLA A2-positive donors were co-cultivated for seven days with irradiated (8,000 rads) T2 cells presensitized with synthetic peptides (37). On days 7 and 14, these cultures were restimulated with peptide-sensitized T2 cells. After 18 days of culture in growth medium, the cells were used as polyclonal effectors in a standard 51Cr-release assay against peptide-sensitized autologous PHA blasts.
- Peptides synthesized by the Merrifield solid phase method, were purchased from Chiron Mimotopes (Melbourne, Australia), dissolved in dimethyl sulphoxide, and diluted in serum-free RPMI 1640 medium for use in standard CTL assays.
- HLA A2 binding peptides within the gp85 and gp350 antigens were identified using a protocol as described in Example 1. These predicted peptides were then used in a standard MHC stablization assay using T2 cells. Briefly, T2 cells (2 ⁇ 10 5 ) were incubated with 200 ⁇ l of each of the peptides (200 ⁇ g/ml) at 26° C. for 14-16 h, followed by incubation at 37° C. for 2-3 h. After the incubations. HLA A2 expression was measured by FACS using a monoclonal HLA A2-specific antibody (MA2.1: ATCC).
- MA2.1 monoclonal HLA A2-specific antibody
- Recombinant vaccinia constructs encoding the EBV structural antigens gp350 (Vacc.gp350) and gp85 (Vacc.gp85), and a vaccinia virus construct made by insertion of the pSC11 vector alone and negative for thymidine kinase (Vacc.TK ⁇ ) have been previously described (38).
- Target cells were infected with recombinant vaccinia virus at a mutiplicity of infection (MOI) of 10:1 for 1 h at 37° C., as described earlier (6,12). After overnight infection, cells were washed with growth medium and processed for CTL assays or for immunoblotting to assess the expression of recombinant EBV antigens (11).
- MOI mutiplicity of infection
- Target cells were either infected with recombinant vaccinia viruses or pre-sensitized with synthetic peptide epitopes and then incubated with 51Cr for 90 min. Following incubation, these cells were washed in growth medium and used as targets in a standard 5 h 51Cr-release assay (16).
- HLA A2/K b transgenic mice used in this study have been described elsewhere (39). These mice express a chimeric class I molecule composed of the alpha 1 & 2 domains of the human A*0201 allele and the alpha 3 domains of the mouse H-2Kb class I molecules. Peptide immunizations were carried out as described by Vitello and colleagues (40). Briefy, these animals were twice immunized (at a 14 day interval) subcutaneously with 50 ug/mouse of CTL epitopes emulsified in IFA together with 5 ug of Tetanus Toxoid as a source of help.
- mice were assessed for gp350- and gp85-specific CTL response.
- splenocytes (3 ⁇ 10 6 cells/ml) were cocultured with syngeneic, irradiated (2000 rad) peptide-coated LPS blasts (3 ⁇ 10 5 cells/ml) and 3 ug/ml human B2-microglobulin.
- CTL activity was tested on day 6 using a standard 51Cr-release assay.
- mice were immunized with CTL epitopes as described above. On day 28, mice were challenged with Vacc.gp85 and Vacc.gp350 intraperitonealy (1 ⁇ 10 7 pfu in 100 ul PBS). After four days of challenge, these animals were sacrificed and vaccinia titres measured in both ovaries by plaque assay on confluent CV1 cells.
- HLA A2-restricted epitopes within gp8S and gp350 the amino acid sequence was analyzed by a computer program designed to predict HLA-binding peptides, based on an estimation of the half-time disassociation of the HLA-peptide complex (http://bimas.dcrt.nih.gov/molbio/hla_bind/index.html) (18).
- a total of 20 peptides (13 from gp85 and 7 from gp350) with an estimated half-time disassociation score of >100 for gp85 and >50 for gp350 were selected (Table 3). These peptides were then tested for HLA A2 binding efficiency using HLA A2-positive T2 cells.
- HLA A2-binding peptides which included four peptides from gp85 and three peptides from gp350 were next tested for CTL recogniton by effectors from IM patients.
- HLA A2-restricted CTL epitope from EBV latent mambrane protein (LMP1) as a positive control (38).
- LMP1 EBV latent mambrane protein
- PBMCs from three HLA A2-positive IM patients, SB, LP and MG were resuspended in IL2-supplemented growth medium and used as effectors in a standard 51Cr-release assay against HLA-matched PHA blasts sensitized with the gp85, gp350 or LMP1 peptides.
- FIG. 9(A-C) Representative data from two different experiments is shown in FIG. 9(A-C). Effectors from all three IM patients showed clear recognition of the reference LMP1 peptide (YLQQNWWTL (SEQ ID NO: 6)) consistent with our earlier finding that this peptide is recognized by EBV-specific CTLs. More importantly, these IM patients also showed strong recognition of target cells sensitized with selected gp85 or gp350 peptides. Interestingly, each of these individuals showed a distinct pattern of reactivity against these peptides. IM patient SB showed strong reactivity against peptides SLVIVTTFV (SEQ ID NO: 17) (gp85) and VLQWASLAV (SEQ ID NO: 27) (gp350) (FIG.
- gp85 and gp350 include CTL determinants which can bind HLA A2 molecules and are efficiently recognised by ex vivo effectors from IM patients.
- PBMCs from the two donors SB and LP were collected at 24-36 months post IM respectively and were stimulated with T2 cells presensitized with each of the gp85 and gp350 peptides which showed strong HLA A2 binding.
- T2 cells presensitized with each of the gp85 and gp350 peptides which showed strong HLA A2 binding.
- these CTL effector were tested against peptide-sensitized autologous PHA blasts.
- Representative data from polyclonal CTLs from donor SB are presented in FIG. 10.
- CTL effectors from donor SB not only showed strong reactivity against peptides SLVIVTTFV (SEQ ID NO: 17) and VLQWASIAV (SEQ ID NO: 27) but also recognized two other peptides from gp85 (LMIIPLINV (SEQ ID NO: 20) and TLFIGSHVV (SEQ ID NO: 24)).
- Donor LP also showed a similar pattern of CTL lysis.
- peptide TLFIGSHVV SEQ ID NO: 24
- HLA A2/Kb transgenic mice were used as an experimental model to address this issue. These mice express a chimeric class I molecule composed of the alpha 1 & 2 domains of the human A*0201 allele and the alpha 3 domain of the mouse H-2Kb class I molecules. These animals were immunized subcutaneously with gp350 or gp85 CTL epitopes emulsified in IFA together with Tetanus Toxoid as a source of help.
- the SLVIVTTFV (SEQ ID NO: 17) and TLFIGSHVV (SEQ ID NO: 24) peptides from gp85 and the VLQWASLAV (SEQ ID NO: 27) peptide from gp350 were used for immunisation. Two weeks following immunization, specific CTL response was assessed in each mouse using splenocytes or pooled inguinal lymph node cells as effectors. Data presented in FIG.
- HLA A2/K b mice were challenged with 10 7 pfu of recombinant vaccinia virus encoding either gp85 or gp350. After four days of challenge, these animals were sacrificed and vaccinia titres measured in both ovaries by plaque assay on confluent CV1 cells. Data from one such experiment is presented in FIG. 12. Animals immunised with gp85 and gp350 epitopes showed very low to undetectable virus in their ovaries, while in naive mice very high titres of vaccinia virus were detected. This protection correlated with strong induction of epitope-specific CTL responses detected in the splenocytes and lymph node cells collected four weeks after primary peptide vacciniation in HLA A2/Kb transgenic mice.
- a vaccine capable of either blocking primary EBV infection or significantly reducing the EBV load during primary infection may be adequate to avert clinical symptoms.
- a similar vaccine will also be able to reduce the immediate risk of lymphoproliferative disease in transplant patients receiving immunosuppressive therapy.
- EBV-associated malignancies such as BL, NPC, and HD arise in patients years after their primary infection, and protection from these longer-term consequences would require a vaccine that ideally confers sterile immunity and prevents the establishment of the carrier state.
- EBV structural antigens primarily gp350
- gp350 is a likely vaccine candidate was based initially upon the observation that this glycoprotein is the principal target of the virus-neutralizing antibody response (41).
- development of neutralizing antibodies in vaccinated animals does not always shows limited correlation with protection from EBV infection, although recent results have suggested a role for gp350-specific CTLs in this protection (34).
- ex vivo effectors from patient LP also recognised target cells infected with Vacc.gp350 and Vacc.gp85.
- the level of ex vivo CTL lysis directed to epitopes from structural antigens was consistently higher than those seen in the same assays against HLA A2-restricted CTL epitopes from a latent antigen.
- mice expressing the human HLA A2 antigen, are capable of (a) generating structural antigen-specific CTL responses and (b) reducing infection with a recombinant vaccinia virus infection expressing the gp350 or gp85 antigen.
- These mice not only showed induction of a strong CTL response following immunization but also acquired strong resistance to virus infection.
- CTL epitopes from the EBV structural antigens with latent antigen epitopes generating a chimeric protein that fuses the important immunogenic determinants from the two different types of antigens to design an effective vaccine.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides cytotoxic Epstein-Barr virus (EBV) T-cell epitopes derived from EBV structural antigens. Preferred epitopes include YLLEMLWRL (SEQ ID NO: 1), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), YLQQNWWTL (SEQ ID NO: 6), LLLALLFWL (SEQ ID NO: 2), LLVDLLWLL (SEQ ID NO: 3), LLLIALWNL (SEQ ID NO: 4), WLLLFLAIL (SEQ ID NO: 5), TLLVDLLWL (SEQ ID NO: 7), LLWLLLFLA (SEQ ID NO: 8), ILLIIALYL (SEQ ID NO: 9), VLFIFGCLL (SEQ ID NO: 10), RLGATIWQL (SEQ ID NO: 11), ILYFIAFAL (SEQ ID NO: 15), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), LIPETVPYI (SEQ ID NO: 26), VLQWASLAV (SEQ ID NO: 27) and QLTPHTKAV (SEQ ID NO: 29). The present invention also provides methods of treating or preventing EBV infection in subjects which involve administration of EBV cytotoxic T-cell epitopes.
Description
- The present invention relates to methods of treating or preventing EBV infections. The present invention also relates to cytotoxic T-cell (CTL) epitopes within Epstein-Barr virus (EBV) structural and latent antigens, and to subunit vaccines and nucleic acid vaccines which include these epitopes.
- It is now well established that long-term protection from persistent viral infection requires the development of virus-specific memory T cells which recognize viral antigens in association with either class I or class II MHC molecules. Since immunization with whole viral proteins is unable to elicit an efficient CTL response, interest has been directed towards designing vaccines based on defined epitope sequences. This is particularly the case with oncogenic viruses, since individual viral genes introduced in recombinant vectors have the potential to initiate tumorgenic processes. Two broad approaches are currently being considered to design an effective vaccine for controlling Epstein-Barr virus (EBV) associated diseases (for review see ref. (7)). These include directing immune responses to either EBV structural antigens or latent antigens.
- In the last few years, most of the vaccine development efforts have concentrated on the use of a subunit preparation of gp350 (recombinant and affinity purified) and have been directed towards blocking virus attachment to the target cell in the oropharynx (31). The general approach has been to immunize cotton-top marmosets with gp350 and determine their ability to restrict the outgrowth of EBV-positive lymphomas in these animals. Indeed, highly purified gp350, when administered subcutaneously in conjunction with adjuvants (muramyl dipeptide or ISCOMS), induced high levels of serum neutralizing antibodies and inhibited tumor formation in cotton-top tamarins (32). A number of recombinant vectors including, vaccinia-gp350 and adenovirus 5-gp350 have also been successfully used in these animals to block tumor outgrowth (33). The precise mechanism by which gp350 affords protection from lymphomas in cotton-top tamarins remains unclear. The fact that development of neutralizing antibody titres in vaccinated animals does not always correlate with protection indicates that gp350-specific T cell-mediated immune responses may also have an effector role (34). Furthermore, Yao and colleagues (35) showed that very low levels of neutralizing anti-gp350 antibodies are present in the saliva of healthy EBV-immune donors, which suggests that such antibodies are unlikely to be the basis of long-term inmmunity in healthy seropositive individuals. It has been postulated that gp350 specific T cell-mediated immune responses may have an effector role in protection. There has been no identification to date, however, of CTL epitopes within the EBV structural antigens.
- Post-transplant lymphoproliferative disease (PTLD) that arises in organ transplant patients is an increasingly important clinical problem. Histological analysis of PTLD shows a quite complex clonal diversity ranging from polymorphic B lymphocyte hyperplasia to malignant monoclonal lymphoma. This range of pathology encompasses the collective term PTLD while the lymphomas are frequently referred to as immunoblastic lymphomas(IL). This condition is clearly associated with the proliferation of Epstein-Barr virus (EBV) infected B cells which are carried for life in all previously infected individuals (about 80% of adults and 20% of children 7 years) (45, 46, 47, 49). These EBV-infected B cells are normally restricted in their growth in vitro and in vivo by virus-specific cytotoxic T cells (CTLs) which recognise epitopes included within the EBV latent proteins (see below) (48). Immunosuppression inhibits these specific CTL and results in an expansion of the pool of EBV-infected B cells and the emergence of the clinical problems associated with PTLD. It is known that the individuals at greatest risk of PTLD are EBV seronegative recipients who receive a transplant from a seropositive donor (Crawford and Thomas, 1993). Immunisation of EBV seronegative graft recipients prior to engraftment will greatly reduce the risk of PTLD.
- The role of the immunue system in the rejection of virus-associated cancers has also been the subject of intense study recently. The hypothesis under investigation is that many neoplasms express viral antigens that should potentially enable them to be recognized and destroyed by the immune system, including both T helper cells and cytotoxic T lymphocytes (CTL). There is now compelling evidence that most of the Epstein-Barr virus (EBV)-associated malignancies escape this potent virus-specific CTL response by restricting viral gene expression (7.20,21). For malignancies such as nasopharyngeal carcinoma (NPC) and Hodgkin's disease (HD), EBV nuclear antigen 1 (EBNA1) and latent membrane protein 1 (LMP1) are the only antigens consistently expressed and are therefore the potential target antigens for any future vaccine designed to control these tumors (3,28). Since it is well established that immunization with whole viral proteins does not elicit an efficient CTL response, interest has been directed towards developing peptide vaccines based on defined epitope sequences.
- Results obtained by the present inventors indicate that CTL epitopes within EBV structural and latent proteins may be effective in providing antiviral immunity against EBV infection. In particular, the present inventors have analysed the latent antigen LMP1 sequence, using peptide stablization assays, and found that this antigen includes potential CTL epitopes. Following in vitro activation with these peptides, both polyclonal and clonal CTLs from HLA A2-positive donors showed strong reactivity against target cells expressing the LMP1 antigen. Moreover, lymphoblastoid cell lines (LCL), expressing different HLA A2 supertypes were efficiently recognized by these CTLs, a result that has important implications for the design of an anti-viral vaccine aimed at protecting different ethnic populations.
- The present inventors have also found that CTLs from acute infectious mononucleosis (IM) patients display strong reactivity against the EBV structural antigens gp85 and gp350. In addition, specific CTL epitopes within EBV structural antigens gp85 and gp350 have been identified for the first time. Importantly, prior immunisation of HLA A2/Kb transgenic mice with these gp350 and gp85 CTL epitopes induced a strong epitope-specific CTL response and afforded protection against gp85- or gp350-expressing vaccinia virus challenge. These results provide evidence, for the first time, of the existence of CTL epitopes in EBV structural proteins and show that they may be used for establishing strong anti-viral immunity against EBV infection.
- Accordingly, in a first aspect the present invention provides a cytotoxic Epstein-Barr virus (EBV) T-cell epitope, the epitope being derived from an EBV structural antigen.
- In a preferred embodiment of the first aspect of the present invention, the EBV structural antigen is gp85 or gp350.
- In a second aspect the present invention provides a cytotoxic Epstein-Barr virus T-cell epitope, the epitope being selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), YLQQNWWTL (SEQ ID NO: 6), LLLALLFWL (SEQ ID NO: 2), LLVDLLWLL (SEQ ID NO: 3), LLLIALWNL (SEQ ID NO: 4), WLLLFLAIL (SEQ ID NO: 5), TLLVDLLWL (SEQ ID NO: 7), LLWLLLFLA (SEQ ID NO: 8), ILLIIALYL (SEQ ID NO: 9), VLFIFGCLL (SEQ ID NO: 10), RLGATIWQL (SEQ ID NO: 11), ILYFIAFAL (SEQ ID NO: 15), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), LIPETVPYI (SEQ ID NO: 26), VLQWASLAV (SEQ ID NO: 27) and QLTPHTKAV (SEQ ID NO: 29).
- In a third aspect the present invention provides a subunit vaccine including a cytotoxic Epstein-Barr virus (EBV) T-cell epitope according to the first aspect of the present invention.
- In a preferred embodiment, the subunit vaccine includes at least one T-cell epitope selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), YLQQNWWTL (SEQ ID NO: 6), LLLALLFWL (SEQ ID NO: 2), LLVDLLWLL (SEQ ID NO: 3), LLLIALWNL (SEQ ID NO: 4), WLLLFLAIL (SEQ ID NO: 5), TLLVDLLWL (SEQ ID NO: 7), LLWLLLFLA (SEQ ID NO: 8), ILLIIALYL (SEQ ID NO: 9), VLFIFGCLL (SEQ ID NO: 10), RLGATIWQL (SEQ ID NO: 11), ILYFIAFAL (SEQ ID NO: 15), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), LIPETVPYI (SEQ ID NO: 26). VLQWASLAV (SEQ ID NO: 27) and QLTPHTKAV (SEQ ID NO: 29).
- In a preferred aspect of the present invention the epitope is selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YLQQNWWTL (SEQ ID NO: 6), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), and VLQWASLAV (SEQ ID NO: 27).
- In a further preferred embodiment, the subunit vaccine includes one or more additional cytotoxic EBV T-cell epitopes. The additional cytotoxic EBV T-cell epitope(s) may be selected from those described in WO 97/45444, the entire contents of which are incorporated herein by reference.
- In a further preferred form of the present invention the vaccine includes a water-in-oil formulation. It is further preferred that the vaccine includes at least one antigen to which the individual will mount an anamnestic response in addition to the at least one cytotoxic T-cell epitope.
- The at least one antigen is preferably selected from the group consisting of tetanus toxoid. diphtheria toxoid,Bordetella pertussis antigens, poliovirus antigens, purified protein derivative (PPD), gp350 protein (Thorley-Lawson, D. A. and Poodry, G. A. (1982). Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J. Virol. 43, 730-736), helper epitopes and combinations thereof and is preferably tetanus toxoid.
- It is preferred that the water-in-oil formulation is Montanide ISA 720. Additional information regarding this formulation can be found in WO 95/24926, the disclosure of which is incorporated herein by cross reference.
- The subunit vaccine may also be formulated using ISCOMs. Further information regarding ISCOMs can be found in Australian Patent Nos. 558258, 590904, 632067, 589915, the disclosures of which are included herein by cross reference.
- In a fourth aspect the present invention provides an isolated nucleic acid sequence encoding a cytotoxic Epstein-Barr virus (EBV) T-cell epitope according to the first aspect of the present invention.
- In a preferred embodiment, the isolated nucleic acid sequence encodes at least one of the cytotoxic T-cell epitopes selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), YLQQNWWTL (SEQ ID NO: 6), LLLALLFWL (SEQ ID NO: 2), LLVDLLWLL (SEQ ID NO: 3), LLLIALWNL (SEQ ID NO: 4), WLLLFLAIL (SEQ ID NO: 5), TLLVDLLWL (SEQ ID NO: 7), LLWLLLFLA (SEQ ID NO: 8), ILLIIALYL (SEQ ID NO: 9), VLFIFGCLL (SEQ ID NO: 10), RLGATIWQL (SEQ ID NO: 11), ILYFIAFAL (SEQ ID NO: 15), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), LIPETVPYI (SEQ ID NO: 26), VLQWASLAV (SEQ ID NO: 27) and QLTPHTKAV (SEQ ID NO: 29).
- As will be appreciated by those skilled in the field the nucleic acid sequence can be delivered as naked nucleic acid or using a suitable viral or bacterial vectors. Suitable bacterial vectors include the bacteria Salmonella spp. Suitable viral vectors include, for example, retroviral vectors, adenoviral vectors and vaccinia vectors. An example of a suitable vaccinia vector is a modified Vaccinia Ankara vector.
- Vectors suitable for delivery of nucleic acid sequences have previously been described. For example, alphavirus vectors have become widely used in basic research to study thestructure and function of proteins and for protein production purposes. Development of a variety of vectors has made it possible to deliver foreignsequences as naked RNA or DNA, or as suicide virus particles produced using helper vector strategies. Preliminary reports also suggest that these vectors may be useful for in vivo applications where transient, high-level protein expression is desired, such as recombinant vaccines. The initial studies have already shown that alphavirus vaccines can induce strong humoral and cellular immune responses with good immunological memory and protective effects. See, for example, Tubulekas I., Berglund P., Fleeton M., and Liljestrom P. (1997) Alphavirus expression vectors and their use as recombinant vaccines: a minireview,Gene 190(1):191-195.
- Recombinant pox viruses have been generated for vaccination against heterologous pathogens. Amongst these, the following are notable examples. (i) The engineering of the Copenhagen strain of vaccinia virus to express the rabies virus glycoprotein. When applied in baits, this recombinant has been shown to vaccinate the red fox in Europe and raccoons in the United States, stemming the spread of rabies virus infection in the wild. (ii) A fowlpox-based recombinant expressing the Newcastle disease virus fusion and hemagglutinin glycoproteins has been shown to protect commercial broiler chickens for their lifetime when the vaccine was administered at 1 day of age, even in the presence of maternal immunity against either the Newcastle disease virus or the pox vector. (iii) Recombinants of canarypox virus, which is restricted for replication to avian species, have provided protection against rabies virus challenge in cats and dogs, against canine distemper virus, feline leukemia virus, and equine influenza virus disease. In humans, canarypox virus-based recombinants expressing antigens from rabies virus. Japanese encephalitis virus, and HIV have been shown to be safe and immunogenic. (iv) A highly attenuated vaccinia derivative, NYVAC. has been engineered to express antigens from both animal and human pathogens. Safety and immunogenicity of NYVAC-based recombinants expressing the rabies virus glycoprotein, a polyprotein from Japanese encephalitis virus, and seven antigens from Plasmodium falciparum have been demonstrated to be safe and immunogenic in early human vaccine studies. See, for example, Paoletti E. (1996) Applications of pox virus vectors to vaccination: an update,Proc Natl Acad Sci USA, 93(21):11349-11353.
- Progress towards effective vaccines to control internal parasites, especially those affecting mucosal compartments, has been inhibited by the combined problems of the antigenic complexity of parasites and the lack of understanding of the host response. However, the accumulation of information regarding regulation of mucosal immunity has enabled a reappraisal of vaccination options to provide appropriate mucosal effector responses. The pivotal role of T cell influences, and in particular the contribution of cytokine signals, has been clearly established from in vitro studies, but data emerging from our laboratories provide evidence for these effects in vivo. We have demonstrated the role of T cells in determining the outcome of an intestinal response and propose a role for local Th2 cytokine production in this regard. To support this proposition, the distribution of cytokine mRNA has been determined by in situ hybridisation techniques in normal and parasitised animals. Further, we have shown that in the absence of Th2 cytokines (using gene knockout animals) mucosal responses are grossly deficient; we have also shown that this defect can be overcome by vector-directed gene therapy. These studies have indicated that new mucosal immunisation opportunities exist by combining traditional immunisation approaches with strategies to upregulate local cytokine production. However, the success of these new strategies will depend on selection of highly immunogenic subunit antigens, coupled with techniques for cytokine manipulation and delivery with appropriate adjuvant/vehicle formulations. This paper reviews delivery technologies available to chaperone labile antigenic and genetic material to appropriate sites for mucosal stimulation after systemic or oral administration. See, for example, Sutter G. et al (1994) A recombinant vector derived from the host range-restricted and highly attentuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.Vaccine 12:1032-1040; and Husband A. J., Bao S., McClure S. J., Emery D. L., Ramsay A. J. (1996) Antigen delivery strategies for mucosal vaccines, Int J Parasitol 8-9:825-834.
- AttenuatedSalmonella typhi vaccine strain CVD 908, which harbors deletion mutations in aroC and aroD, has been shown to be well-tolerated and highly immunogenic, eliciting impressive serum antibody, mucosal IgA and cell-mediated immune responses. A further derivative prepared by introducing a deletion in htrA (which encodes a heat-shock protein that also has activity as a serine protease in CVD 908 resulted in CVD 908-htrA. In
phase 1 clinical trials, CVD 908-htrA appears very attractive as a live oral vaccine candidate. Both CVD 908 and CVD 908-htrA are useful as live vector vaccines to deliver foreign antigens to the immune system. Conditions that enhance the expression and immunogenicity of foreign antigens carried by CVD 908 and CVD 908-htrA are being investigated. For a review of Salmonella vectors, see Levine M. M., Galen J., Barry E., Noriega F., Chatfield S., Sztein M., Dougan G. And Tacket C (1996) Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors, J Biotechnol 44(1-3): 193-196. - The isolated nucleic acid sequences may be in the form of nucleic acid vaccines. Further information regarding nucleic acid vaccines can be found in WO 96/03144 and in Suhrbier A (1997), Multi-epitope DNA vaccines,Immunol Cell Biol 75(4):402-408 the disclosures of which are incorporated herein by cross reference.
- In a fifth aspect the present invention provides an isolated polypeptide, the polypeptide including at least one epitope according to the first or second aspects of the present invention.
- The vaccines of the present invention may be used prophylactically or therapeutically.
- The CTL epitopes of the present invention may be synthesised using techniques well known to those skilled in this field. For example, the CTL epitopes may be synthesised using solution synthesis or solid phase synthesis as described, for example, in
Chapter 9 entitled “Peptide Synthesis” by Atherton and Sheppard which is included in a publication entitled “Synthetic Vaccines” edited by Nicholson and published by Blackwell Scientific Publications. Preferably a solid phase support is utilised which may be polystyrene gel beads wherein the polystyrene may be cross-linked with a small proportion of divinylbenzene (e.g. 1%) which is further swollen by lipophilic solvents such as dichloromethane or more polar solvents such as dimethylformamide (DMF). The polystyrene may be functionalised with chloromethyl or anionomethyl groups. Alternatively, cross-linked and functionalised polydimethyl-acrylamide gel is used which may be highly solvated and swollen by DMF and other dipolar aprolic solvents. Other supports can be utilised based on polyethylene glycol which is usually grafted or otherwise attached to the surface of inert polystyrene beads. In a preferred form, use may be made of commercial solid supports or resins which are selected from PAL-PEG, PAK-PEG, KA, KR or TGR. - In solid state synthesis, use is made of reversible blocking groups which have the dual function of masking unwanted reactivity in the a-amino, carboxy or side chain functional groups and of destroying the dipolar character of amino acids and peptides which render them inactive. Such functional groups can be selected from t-butyl esters of the structure RCO—OCMe3—CO—NHR which are known as t-butoxy carboxyl or ROC derivatives. Use may also be made of the corresponding benzyl esters having the structure RCO—OCH2—C6H5 and urethanes having the structure C6H5CH2O CO—NHR which are known as the benzyloxycarbonyl or Z-derivatives. Use may also be made of derivatives of fluorenyl methanol and especially the fluorenyl-methoxy carbonyl or Fmoc group. Each of these types of protecting group is capable of independent cleavage in the presence of one other so that frequent use is made, for example, of BOC-benzyl and Fmoc-tertiary butyl protection strategies.
- Reference also should be made to a condensing agent to link the amino and carboxy groups of protected amino acids or peptides. This may be done by activating the carboxy group so that it reacts spontaneously with a free primary or secondary amine. Activated esters such as those derived from p-nitrophenol and pentafluorophenyl may be used for this purpose. Their reactivity may be increased by addition of catalysts such as 1-hydroxybenzotriazole. Esters of triazine DHBT (as discussed on page 215-216 of the abovementioned Nicholson reference) also may be used. Other acylating species are formed in situ by treatment of the carboxylic acid (i.e. the Nα-protected amino acid or peptide) with a condensing reagent and are reacted immediately with the amino component (the carboxy or C-protected amino acid or peptide). Dicyclohexylcarbodiimide, the BOP reagent (referred to on page 216 of the Nicholson reference), O'Benzotriazole-N,N, N′N′-tetra methyl-uronium hexaflurophosphate (HBTU) and its analogous tetrafluroborate are frequently used condensing agents.
- The attachment of the first amino acid to the solid phase support may be carried out using BOC-amino acids in any suitable manner. In one method BOC amino acids are attached to chloromethyl resin by warming the triethyl ammonium salts with the resin. Fmoc-amino acids may be coupled to the p-alkoxybenzyl alcohol resin in similar manner. Alternatively, use may be made of various linkage agents or “handles” to join the first amino acid to the resin. In this regard, p-hydroxymethyl phenylactic acid linked to aminomethyl polystyrene may be used for this purpose.
- As will be readily appreciated by those skilled in the art the LMP1, gp85 and gp350 epitopes and vaccines of the present invention can be used to treat and to protect against EBV. Further, given the possible greater involvement of EBV infection in immunocompromised individuals, the present invention may have particular application in the treatment and protection of individuals having decreased immune function, eg transplant patients. Importantly, the present inventors have found that EBV transformed lymphoblastoid cell lines expressing different HLA A2 supertypes are efficiently recognised by LMP1-specific CTL clones. This highlights the potential for the design of an antiviral vaccine aimed at treating and protecting different ethnic populations.
- Accordingly, in a sixth aspect the present invention provides a method of preparing a composition for use in inducing CTLs in a subject, the method including admixing at least one epitope according to the first or second aspects of the present invention with at least one pharmaceutical acceptable carrier, diluent or excipient.
- In a seventh aspect the present invention provides a method of reducing the risk of EBV infection in a subject which method includes administering to the subject an effective amount of:
- (1) at least one CTL epitope according to the first or second aspects of the present invention;
- (2) a subunit vaccine according to the third aspect of the present invention;
- (3) a nucleic acid sequence according to the fourth aspect of the present invention;
- (4) a vector according to the fourth aspect of the present invention; or
- (5) a polypeptide according to the fifth aspect of the present invention.
- In an eighth aspect the present invention provides a method of treating or preventing nasopharyngeal carcinoma or Hodgkin's disease in a subject which method includes administering to the subject an effective amount of at least one CTL epitope derived from an EBV structural or latent antigen.
- By “effective amount” we mean a quantity of the epitope which is sufficient to induce or amplify a CTL response against an EBV antigen.
- In a preferred embodiment of the eighth aspect of the present invention, the EBV structural antigen is gp85 or gp350 and the latent antigen is LMP1 or LMP2. In a further preferred embodiment the CTL epitope is an epitope as defined in the second aspect of the present invention.
- The present inventors have also made the surprising finding that NPC cells which are recognised by CTL clones are subject to CTL lysis. This finding has important implications for the design of vaccines to control NPC tumours in vivo.
- In an ninth aspect the present invention provides a method of treating or preventing growth of NPC or HD cells in a subject in need thereof which method includes administering to the subject at least one CTL epitope derived from an EBV structural or latent antigen.
- In a preferred embodiment of the ninth aspect of the present invention, the EBV CTL epitopes are derived from the gp85 or gp350 antigens. In a further preferred embodiment, the EBV CTL epitopes are derived from the LMP1 or LMP2 antigens. Preferably, the CTL epitopes are derived from the LMP1 antigen.
- In a tenth aspect the present invention provides a method of treating or preventing the growth of NPC or HD cells in a first subject which method includes transferring to the subject EBV-specific CTLs which recognise NPC or HD cells.
- In a preferred embodiment the EBV-specific CTLs are obtained from NPC patients by in vitro stimulation of CTLs by exposure to EBV CTL epitopes. Alternatively, the EBV-specific CTLs may be obtained from a second subject, wherein the second subject is infected with EBV but does not have NPC.
- In a further preferred embodiment of the tenth aspect of the present invention, the EBV-specific CTLs are LMP1 and/or LMP2-specific CTLs.
- In an eleventh aspect the present invention provides a method of reducing the risk of infectious mononucleosis or post transplantation lymphoproliferative disease in a subject which method includes administering to the subject an effective amount of:
- (1) at least one CTL epitope according to the first or second aspects of the present invention;
- (2) a subunit vaccine according to the third aspect of the present invention;
- (3) a nucleic acid sequence according to the fourth aspect of the present invention;
- (4) a vector according to the fourth aspect of the present invention; or
- (5) a polypeptide according to the fifth aspect of the present invention.
- The terms “comprise”, “comprises” and “comprising” as used throughout the specification are intended to refer to the inclusion of a stated component or feature or group of components or features with or without the inclusion of a further component or feature or group of components or features.
- In order that the nature of the present invention may be more clearly understood forms thereof will now be described with reference to the following examples and figures.
- FIG. 1: MHC stablization analysis on T2 cells using potential HLA A2 binding peptides within LMP1. T2 cells were initially incubated with 200 μl of each of the peptides (200 μg/ml) for 14-16 h at 26° C. followed by incubation at 37° C. for 2-3 h. HLA A2 expression on these cells was analysed by FACS using the BB7.2 antibody. The dotted line indicates the background mean fluorescence intensity for HLA A2 on T2 cells without any peptide. The LMP1 peptides showing significant stablization of HLA A2 molecules on T2 cells are indicated by arrows.
- FIG. 2: Recognition of LMP1 peptides by polyclonal CTLs from an HLA A2-positive donor SB. PBMC from donor SB were co-cultivated for seven days with irradiated T2 cells sensitized with synthetic peptides (indicated on the Y-axis). On
day 10, these cells were used as polyclonal effectors in a standard 51Cr-release assay against peptide-sensitized (1 μg/ml) autologous PHA blasts. An effector:target ratio of 20:1 was used in the assay. Data from one representative experiment out of three is shown. Results are expressed as percent specific lysis. - FIG. 3: Specific lysis by an EBV-specific CTL clone (SB7) from donor SB of autologous LCLs and autologous CD40 B cells infected with Vacc.EBNA1, 2, 3, 4, 5, 6, LMP1, LMP2A and Vacc.TK−(panel A). Target cells were infected for 12-14 h (M.O.I=10:1) with vaccinia constructs and processed for the standard51Cr-release assay. Vacc.TK− was used as a control recombinant vaccinia. To further confirm the LMP1 specificity of the SB7 clone, LMP1-and HLA A2-positive BL cell lines (BJAB.MTLM6 or Mutu cl.59) and LMP1-negative, HLA A2-positive BL cell lines (BJAB.gpt1 and Mutu cl.216) were used as targets in a standard 51Cr-release assay (panel B). An effector:target ratio of 4:1 was used in both assays. Results are expressed as percent specific lysis.
- FIG. 4: CTLp frequencies for the LMP1 epitopes YLQQNWWTL (SEQ ID NO: 6) (A) and YLLEMLWRL (SEQ ID NO:1) (B) in HLA A2-positive donor are shown. Using limiting dilution analysis, the frequencies of CTLp for peptides YLQQNWWTL (SEQ ID NO: 6) (A) and YLLEMLWRL (SEQ ID NO: 1) (B) were estimated in peripheral blood lymphocytes from donor SB. PBMC from this donor was stimulated with peptides sensitized PBMC as described in the “Materials and Methods” section. Reciprocal values of responder frequencies (f1) are indicated. The shaded areas indicate 95% confidence limits.
- FIG. 5: CTL recognition of LCLs expressing different supertypes of HLA A2 by the SB7 CTL clone. All LCLs used in this assay were transformed with the B95.8 EBV isolate. The HLA A2 subtyping for each LCL was assigned by the 12th Histocompatability workshop. An effector:target ratio of 4:1 was used in both the assay. Results are expressed as percent specific lysis. Data from one representative experiment out of four is shown.
- FIG. 6: Effect of variant LMP1 peptides on the HLA A2 binding (panel A) and CTL recognition (panel B). For HLA A2 binding analysis on T2 cells were initially incubated with 200 μl of each of the peptides (200 μg/ml) for 14-16 h at 26° C. followed by incubation at 37° C. for 2-3 h. HLA A2 expression on these cells was analysed by FACS using BB7.2 antibody (panel A). The dotted line indicates the background mean fluorescence intensity for HLA A2 on T2 cells without any peptide. For CTL recognition of the variant and prototypic HLA A2-restricted LMP1 epitope. PHA blasts from donor SB were sensitized with serial dilutions of each of the peptides and then exposed to the SB7 CTL clone (panel B) at an effector:target ratio of 4:1. Results are expressed as percent specific lysis. Data from one representative experiment out of three is shown. Amino acid changes in the variant peptides are indicated by bold letters.
- FIG. 7: CTL recognition of NPC cells and LCLs by EBV-specific HLA A11-restricted CTL clones CM9 (a & c) and CM29 (b & d). Vacc.EBNA4, Vacc.TK infected or peptide sensitized C15NPC cells (a & b) were exposed to CTL clones at different effector to target ratios and the level of CTL lysis was compared to a
type 2 LGLs (CM/Ag876 LCL). As a positive control target cells were either presensitized with IVTDFSVIK peptide (a & c), or AVFDRKSDAK peptide (b & d). The results were expressed as per cent specific lysis. - FIG. 8: MHC stabilization analysis on T2 cells using potential HLA A2 binding peptides within gp85 (panel A) and gp350 (panel B). T2 cells were initially incubated with 200 Tl of each of the peptides (200 Tg/ml) for 14-16 h at 26° C. followed by incubation at 37° C. for 2-3 h. HLA A2 expression on these cells was analysed by FACS using the BB7.2 antibody. The dotted line indicates the background mean fluorescence intensity for HLA A2 on T2 cells without any peptide. The gp85 and gp350 peptides showing significant stabilization of HLA A2 molecules on T2 cells are indicated by arrows.
- FIG. 9: gp85 and gp350-specific ex vivo cytotoxic T cell activity in peripheral blood lymphocytes from IM donors. Panel A, B & C shows ex vivo CTL lysis of peptide-sensitized (1 μg/ml) PHA blasts at two different effector:target (E/T) ratios. Data from IM patient SB, LP and MG are presented in panel A, B and C respectively. Panel D shows ex vivo CTL lysis by peripheral blood lymphocytes from patient LP of target cells infected with recombinant vaccinia encoding either gp85 (Vacc.gp85) or gp350 (Vacc.350) by. Vacc.TK− and Vacc.EBNA2 were used as control in the assay.
- FIG. 10: Recognition of gp85 and gp350 peptides by polyclonal CTLs from an HLA A2-positive IM recovered (36 months post IM) individual. PBMC were co-cultivated for seven days with irradiated T2 cells sensitized with synthetic peptides (indicated on the Y-axis). On day 18, these cells were used as polyclonal effectors in a standard 51Cr-release assay against peptide-sensitized (1 Tg/ml) autologous PHA blasts. An effector:target ratio of 20:1 was used in the assay. Individual peptide stimulated CTL effectors used in this experiments are indicated in the figure. Data from one representative experiment out of three is shown. Results are expressed as percent specific lysis.
- FIG. 11: Immunization of HLA A2/Kb mice with gp85 and gp350 CTL epitopes induces strong CTL response. Animals were twice immunized (at a 14 day interval) subcutaneously with individual CTL epitope with Tetanus Toxoid as a source of help. Four weeks following peptide immunization, animals were assessed for gp350- and gp85-specific CTL response. Panel A, B & C shows CTL activity in splenocytes from two mice immunized with VLQWASLAV (SEQ ID NO: 27) (gp350), TLFIGSHVV (SEQ ID NO: 24) (gp85) and SLVIVTTFV (SEQ ID NO: 17) (gp85) respectively. CTL lysis of target cells sensitized with peptide epitopes are shown as filled symbols, while lysis of unsensitized target cells is shown as empty symbols. Panel D shows CTL activity in pooled inguinal lymphnodes from mice immunised with peptide VLQWASLAV (SEQ ID NO: 27) (▪, □), SLVIVTTFV (SEQ ID NO: 17) (▴, Δ) and TLFIGSHVV (SEQ ID NO: 24) (, ◯). CTL activity was tested on
day 6 using a standard 51Cr-release assay. - FIG. 12: Prior immunisation of HLA A2/Kb mice with gp85 or gp350 CTL epitopes affords protection against recombinant vaccinia virus challenge. Groups of female A2/Kb transgenic mice, either unimmunized or immunized with CTL epitopes, were challenged with Vacc.gp85 and Vacc.gp350 intraperitonealy. After four days of challenge, these animals were sacrificed and vaccinia titre measured in both ovaries by plaque assay on confluent CV1 cells. X-axis shows peptides used for immunization, while Y-axis shows Mean+/−SE vaccinia virus titre in naive and peptide immunized mice. Recombinant vaccinia virus used for challenge in these animals is shown in each panel of the figure.
- Establishment and Maintenance of Cell Lines
- LCLs were established from sero-positive donors by exogenous virus transformation of peripheral B cells using the B95.8 (Type 1) or Ag876 (Type 2) virus isolates. In addition, LCLs transformed with the B95.8 isolate and expressing different HLA A2 supertypes were also used in this study (12th Histocompatability workshop cell panel; EACC). The peptide transporter (TAP)-negative B×T hybrid cell line 174×CEM.T2 (referred to as T2) (22) were used for peptide stablization assays. All cell lines were routinely maintained in RPMI 1640 containing 2 mM glutamine, 100 IU/ml penicillin and 100 ug/ml streptomycin plus 10% foetal calf serum (FCS) (growth medium). Long-term cultures of EBV-negative normal B cell blasts were established as previously described using the CD40 system (referred to as CD40 B cells) (12).
- The Burkitt's lymphoma (BL) cell lines, BJAB.gpt1, BJAB.MTLM6, MUTU cl.59 and MUTU cl.216 were used in this study. These were derived from patients with non-endemic or endemic BL. BJAB.MTLM6 and MUTU cl.59 have previously been shown to express LMP1, while BJAB.gpt1 and MUTU cl.216 are negative for LMP1 (5,27). These BL cell lines were routinely maintained in growth medium.
- To generate phytohaemagglutinin (PHA) blasts, peripheral blood mononuclear (PBMC) cells were stimulated with PHA (Commonwealth Serum Laboratories, Melbourne) and after 3 days, growth medium containing MLA 144 supernatant and rIL-2 was added (2). PHA blasts were propagated with bi-weekly replacement of IL-2 and MLA supernatant (no further PHA added) for up to 6 weeks.
- Virus Isolates
- To isolate resident EBV, spontaneous LCLs were established from a panel of 12 unrelated healthy EBV-seropositive donors by spontaneous outgrowth from PBMC cultured in the presence of 0.1 μg/ml cyclosporin A (19). In addition, virus isolates from eight different NPC samples (from Southeast Asia) were directly sequenced from biopsy material. These isolates were classified as
type 1 EBV based on the DNA sequence divergence within the BAM H1 WYH and E regions of the genome (23,24). - PCR and DNA Sequencing of CTL Epitopes
- Specific oligonucleotide primers flanking the DNA region encoding the LMP1 epitope were selected for PCR amplification. The resulting PCR products were purified using QIAquick spin columns (Qiagen Inc. Chatsworth, Calif.) and sequenced in both directions using a PRISM ready reaction dyedeoxy terminator cycle sequencing kit (Applied Biosystems Inc., Foster City, Calif.) following the manufacturer's protocol.
- Synthesis of Peptides
- Peptides synthesized by the Merrifield solid phase method (16) were purchased from Chiron Mimotopes (Melbourne, Australia). dissolved in dimethyl sulphoxide and diluted in serum-free RPMI 1640 medium for use in standard CTL assays.
- MHC Stabilisation Assays
- To identify the potential HLA A2 binding peptides within LMP1, a computer based program was employed as described elsewhere (http ://bimas.dcrt.nih.gov/molbio/hla_bind/index.html) (18). These predicted peptides were then used in a standard MHC stablization assay using T2 cells as described earlier (1). Briefly, T2 cells (2×105) were incubated with 200 μl of each of the peptides (200 μg/ml) at 26° C. for 14-16 h, followed by incubation at 37° C. for 2-3 h. After the incubations, HLA A2 expression was measured by FACS using a monoclonal HLA A2-specific antibody (MA2.1; ATCC).
- Generation of Polyclonal and Clonal LMP1-Specific CTLs
- To generate polyclonal CTLs, PBMC from HLA A2-positive donors were co-cultivated for seven days with the irradiated (8,000 rads) T2 cells sensitized with synthetic peptides. On day 7, these lymphocytes were restimulated with peptide-sensitized T2 cells. After 10 days of culture in growth medium, the cells were used as polyclonal effectors in a standard51Cr-release assay against peptide-sensitized autologous PHA blasts.
- To generate LMP1-specific CTL clones, PBMC (106/ml) were cultivated with peptide sensitized autologous lymphocytes (responder to stimulator ratio of 4:1) in 2 ml culture wells (Linbro) for 3 days in growth medium. CTL clones, generated by seeding in 0.35% agarose, were established and maintained in growth medium containing highly purified recombinant human IL-2 from E. coli (16), restimulating twice weekly with autologous LCLs. These CTL clones were screened on a panel of recombinant vaccinia-infected autologous CD40 B cells to confirm the antigen specificity (see below).
- Vaccinia Virus Recombinants
- Recombinant vaccinia constructs encoding EBV latent antigens and a vaccinia virus construct made by insertion of the pSC11 vector alone and negative for thymidine kinase (Vacc.TK−) have been previously described (6.11). CD40 B cells were infected with recombinant vaccinia virus at a multiplicity of infection (MOI) of 10:1 for 1 h at 37° C. as described earlier (6.11). After overnight infection, cells were washed with growth medium and processed for CTL assays or for immunoblotting to assess the expression of recombinant EBV antigens (12).
- Cytotoxicity Assay
- Target cells were either infected with recombinant vaccinia viruses or pre-sensitized with synthetic peptide epitopes (wild-type or variant) and then incubated with51Cr for 90 min. Following incubation, these cells were washed in growth medium and used as targets in a standard 5 h 51Cr-release assay (16). In some experiments, monoclonal antibodies (MoAb) specific for the non-polymorphic determinants on MHC class I (W6/32) or class II (L243) antigens were added to define the MHC restriction of the CTL clones.
- Limiting Dilution Analysis (LDA)
- PBMC from HLA A2-positive donors were distributed in graded numbers (two fold dilutions) from 6.25×103 to 5×104 cells per well in round-bottomed microtiter plates. Approximately 5×104 K-irradiated (2,000 rads) peptide sensitized (1 μg/ml) auologous PBMC were added to give a total volume of 100 μl. Twenty-four replicates were used at each concentration in each experiment. Cultures were fed on
days 4 and 7 with 50 μl of medium supplemented with 20U of rIL-2 and 30% (vol/vol) supernatant from MLA-144 cultures. Onday 10, each CTL microculture was split into two replicates and used as effectors in a standard 5 h 51Cr-release assay against autologous PHA blasts precoated with an LMP1 peptide or left uncoated. Wells were scored as positive when the percent specific chromium release for peptide-sensitized target cells exceeded the mean release from untreated control wells by 3 SDs. LDA was performed by the method of maximum likelihood estimation (4). Data from all experiments were compatible with the hypothesis of single-hit kinetics (P>0.4) and precursor estimates are given with 95% confidence limits. - Identification of HLA A2 Binding Peptides within LMP1
- To identify potential HLA A2-restricted epitopes within LMP1. the amino acid sequence was analyzed by a computer program designed to predict HLA-binding peptides, based on an estimation of the half-time disassociation of the HLA-peptide complex (http://bimas.dcrt.nih.gov/molbio/hla_bind/index.html) (18). A total of 11 peptides with an estimated half-time disassociation score of >400 were selected (Table 1). These peptides were then tested for HLA A2 binding efficiency using HLA A2-positive T2 cells. Representative data from a series of experiments is presented in FIG. 1. This analysis showed that six peptides significantly increased the expression of HLA A2 on T2 cells suggesting that these peptides bind to this allele.
- Generation of Polyclonal CTLs Specific LMP1 Peptides
- The data presented above strongly suggested that LMP1 includes sequences which can bind HLA A2 molecules and are therefore potential targets for virus-specific CTLs. To verify this hypothesis, PBMC from two HLA A2-positive EBV immune donors (SB and AS) were stimulated with T2 cells sensitized with each of the HLA A2-binding peptides from LMP1. On
day 10, these effector cells were tested against peptide-sensitized autologous PHA blasts. Represtative data from polyclonal CTLs from donor SB are presented in FIG. 2. Two peptides, YLQQNWWTL (SEQ ID NO: 6) and YLLEMLWRL (SEQ ID NO: 1), showed significant activation of polyclonal CTLs; however, the YLLEMLWRL-stimulated CTLs consistently showed significantly stronger CTL activity when compared to the YLQQNWWTL-stimulated cells. Similar data were also obtained for another HLA A2-positive donor (AS) (data not shown).TABLE 1 Identification of Potential HLA A2 Binding Peptides within LMP1* Score (Estimate half-time disassociation from HLA Ranking Residue Peptide Sequence A2 allele) 1 125-133 YLLEMLWRL (SEQ ID NO:1) 25714.76 2 32-40 LLLALLFWL (SEQ ID NO:2) 9858.69 3 167-175 LLVDLLWLL (SEQ ID NO:3) 2568.45 4 92-100 LLLIALWNL (SEQ ID NO:4) 2317.87 5 173-181 WLLLFLAIL (SEQ ID NO:5) 1302.88 6 159-167 YLQQNWWTL (SEQ ID NO:6) 1252.90 7 166-174 TLLVDLLWL (SEQ ID NO:7) 999.86 8 171-179 LLWLLLFLA (SEQ ID NO:8) 935.11 9 152-160 ILLIIALYL (SEQ ID NO:9) 739.03 10 110-118 VLFIFGCLL (SEQ ID NO:10) 510.60 11 132-140 RLGATIWQL (SEQ ID NO:11) 441.60 - Charaterization of LMP1 CTL Epitope
- To further characterize the CTL epitopes identified by the polyclonal CTLs, virus-specific CTL clones were generated using initial stimulation with peptide sensitized autologous PBMC followed by continous restimulation with irradiated autologous LCLs. Proliferating clones were screened for peptide recognition using the rapid visual assay for CTL specificity (2) and one clone, SB7, clearly recognized the YLLEMLWRL (SEQ ID NO: 1) peptide. No CTL clones specific for YLQQNWWTL (SEQ ID NO: 6) were isolated using this procedure. To further confirm the antigen specificity of the SB7 clone, autologous CD40-stimulated B cells were infected with recombinant vaccinia viruses encoding individual EBV antigens and then exposed to these CTLs. The data presented in FIG. 3A clearly demonstrate that only target cells infected with the LMP1-expressing vaccinia construct were recognized. In addition, only LMP1- and HLA A2-positive BL cell lines (BJAB.MTLM6 or Mutu cl.59) were efficiently lysed by this clone, while BL cells negative for this antigen (BJAB.gpt1 and Mutu cl.216) were not recognized (FIG. 3B). These results confirm that YLLEMLWRL (SEQ ID NO: 1) is an LMP1 CTL epitope that is endogenously processed by virus-infected cells.
- In the next set of experiments we analyzed the frequency of CTL precursors (CTLp) for this epitope in PBMC from HLA A2-positive healthy EBV immune donors by limiting dilution analysis. YLLEMLWRL-specific CTLp were reactivated in vitro by stimulation of PBMCs from donors SB and AS with autologous peptide-sensitized PBMCs. Autologous PHA blasts precoated with peptide YLLEMLWRL (SEQ ID NO: 1) or untreated were used as target cells in a chromium release assay. The representative data in FIG. 4 show that a very low frequency of memory CTL specific for the YLLEMLWRL (SEQ ID NO: 1) epitope were detected in the HLA A2-positive donors AS (1:223,535+/−107,437) and SB (1:252,650+/−122,875).
- To determine whether EBV-transformed LCLs expressing different HLA A2 supertypes could be recognized by clone SB7, a panel of LCLs expressing ten different supertypes of the HLA A2 allele (HLA A*0201-HLA A*0210) were screened in a standard CTL assay. The data presented in FIG. 5 clearly demonstrate that LCLs expressing all the major HLA A2 supertypes except HLA A*0205 were efficiently recognized by the CTL clone SB7. This lysis was significantly inhibited by the HLA class I-specific antibody W6/32. Surprisingly, HLA A2-positive and TAP-negative T2 cells were also recognized by this clone suggesting that the YLLEMLWRL (SEQ ID NO: 1) epitope is endogenously processed through a TAP-independent pathway (FIG. 5).
- Sequence Analysis of the HLA A2-Restricted LMP1 Epitope in Virus Isolates from NPC Patients and Healthy Donors
- Efficient presentation of the LMP1 epitope by HLA A*0201, HLA A*0203 and HLA A*0207, which are common supertypes in the Southeast Asian ethnic population, raised the possibility that this epitope might be important as a potential target epitope for LMP1-expressing NPC. Sequence analysis across this CTL epitope region in virus isolates from eight NPC samples was carried out using LMP1-specific primers. Spontaneous LCLs from healthy EBV immune donors were used as controls in this analysis. Interestingly all EBV isolates from the NPC samples displayed identical substitutions within this epitope (Table 2).
- In contrast, of the 12 virus isolates from healthy EBV immune donors, four encoded a sequence identical to that of the B95.8 isolate, while six displayed a different pattern of alterations within this epitope that differed from those found in the NPC samples. In some isolates leucine at
position 2, methionine atposition 5 and arginine atposition 8 were substituted with phenylalanine, isoleucine and glycine, respectively (Table 2), while in other isolates only the methionine atposition 5 was substituted with isoleucine. Importantly, incubation of T2 cells with these variant peptides (YFLEILWGL (SEQ ID NO: 32) and YLLEILWRL (SEQ ID NO: 33)) significantly increased MHC expression on these cells (FIG. 6A), indicating efficient binding to HLA A2. the YLLEILWRL (SEQ ID NO: 33) peptide was efficiently recognized by the SB7 clone, while no CTL activity was seen in the presence of the YFLEILWGL (SEQ ID NO: 32) peptide (FIG. 6B). The latter result does not rule out the possibility that YFLEILWGL (SEQ ID NO: 32) is an epitope individuals infected with an EBV strain encoding this sequence. The loss of recognition by the clone SB7 is likely to be due an inappropriate T cell receptor interaction with the MHC-peptide complex rather than loss of MHC binding. Thus it is possible that T cells expressing a different T cell receptors are capable of efficiently recognising this HLA binding peptide (8). Interestingly, virus isolates from the other two healthy EBV immune donorsTABLE 2 Sequence of HLA A2-restricted LMP1 epilope (YLLEMLWRL) in EBV isolates from NPC and healthy seropositive individuals. Number HLA A2b of Virus Origin Epilope Sequencea Binding Isolates B95.8 96676TAC TTA TTG GAG ATG CTC TGG CGA CTT96702 ++++ Y L L E M L W R NPC Southeast --- --C --- --- --T --- --- --- --- Asia {open oversize bracket} - F - - I - - - - − 8 Healthy Caucasian --- --- --- --- --- --- --- --- --- donors {open oversize bracket} - - - - - - - - - ++++ 4 Caucasian --- --- --- --- --T --- --- --- --- ++++ 2 {open oversize bracket} - - - - I - - - - Caucasian --- --C --- --- --T --- --- G-G --- ++++ 4 {open oversize bracket} - F - - I - - G - Caucasian --- --C --- --- --T --- --- --- --- − 1 {open oversize bracket} - F - - I - - - - Southeast --- --C --- --- --T --- --- --- --- − 1 Asia {open oversize bracket} - F - - I - - - - - (including one from Southeast Asia) displayed changes within the epitope sequence which were identical to those seen in the NPC samples (Table 2).
- Analysis of Antigen Processing Function of NPC Cells
- To determine whether NPC cells can present endogenously expressed antigens to virus-specific CTLs, tumour cells were either infected with recombinant vaccinia encoding EBNA4 (Vacc.EBNA4) or presensitized with synthetic peptide epitopes. FIG. 7 illustrates the results from an experiment in which recombinant vaccinia-infected NPC cells (C15) were compared with HLA-matched
type 2 LCLs infected with Vacc.EBNA4. Following exposure to EBNA4-specific CTLs, Vacc.EBNA4-infected or peptide sensitized NPC cells were efficiently recognised by both CM19 and CM29 CTL clones. The level of CTL lysis was comparable to that seen for LCLs. These results clearly demonstrate that NPC cells are able to transport sufficient levels of peptides into the ER by TAP-dependent mechanism and can efficiently transport MHC-peptide complexes from the ER to the surface of the cell. - Normal antigen processing function in NPC cells has significant implications for vaccines designed to control these tumours in vivo. Earlier studies have demonstrated that the latent gene expression in NPC is often limited to EBNA1 and the transmembrane proteins, LMP1 and LMP2 (29).
- Since EBNA1 is not recognized by EBV-specific CTLs, there is an increasing emphasis on designing strategies to control NPC around epitopes known to be included within LMP1 (6,17). In view of the data presented in this study, it is reasonable to assume that LMP epitopes will be processed efficiently by NPC cells. An effective approach to control NPC cells in vivo may be to amplify LMP-specific CTL responses in these patients. This might be achieved by two different procedures. Firstly, NPC patients might be immunised with synthetic peptides which include CTL epitopes from LMP1 and/or LMP2. Alternatively. LMP1 and LMP2-specific CTLs from HLA matched healthy virus carriers may be adoptively transferred into NPC patients in a manner analogous to that used to successfully treat EBV-associated polyclonal lymphomas in bone marrow transplant recipients (30).
- Earlier work from various laboratories have shown that the viral phenotype of EBV-associated malignancies is likely to be a very important factor in reducing tumor susceptibility to virus-specific CTL surveillance, since viral antigen expression in these malignant cells in vivo is restricted to either EBNA1, or EBNA1 and LMP1 (9,20,21). Since it is now firmly established that EBNA1 does not include class I-restricted CTL epitopes (6,17), considerable interest has been directed towards identifying potential epitopes within LMP1. The present study was precisely designed to address this issue. One of the limiting factors in identifying epitopes within LMP1 has been the fact that the CTL response to this antigen often constitutes as a minor component of the total virus-specific response (6,17). To overcome this problem we employed a modified protocol to identify potential HLA A2-restricted epitopes within LMP1. An important step in this process was the use of a computer based program developed by Parker and colleagues (18) designed to predict the potential HLA binding peptides within various proteins from human pathogens. Analysis of the LMP1 sequence from the B95.8 EBV isolate revealed a number of potential HLA A2 binding peptides and a large proportion of these were then functionally shown to stabilize HLA A2 molecules on T2 cells. Stimulation of PBMCs with these peptides resulted in the activation of a strong polyclonal CTL response specific for the peptide YLLEMLWRL (SEQ ID NO: 1), while a weaker response was seen for another peptide YLQQNWWTL (SEQ ID NO: 6). The YLLEMLWRL (SEQ ID NO: 1) sequence was confirmed as an LMP1 epitope by isolating a CTL clone (SB7) specific for this peptide. The LMP1 specificity of the SB7 CTL clone was further confirmed by the recombinant vaccinia experiments and efficient lvsis of LMP1 expressing HLA A2-positive BL cells.
- The CTL response characterized in the present report is of interest not only because it is directed against a viral antigen constitutively expressed in many EBV-associated malignancies (HD and NPC) but also because the HLA A2 allele is common in virtually all human populations (13). More importantly, EBV transformed LCLs expressing all the major HLA A2 supertypes were efficiently recognized by the LMP1-specific CTL clone, a result that has important implications for anti-viral vaccine design aimed at protect different ethnic populations. It is important to mention here that the CTL, response to the LMP1 epitope in healthy seropositive individuals constitutes a minor component of the virus-specific CTL response and very low levels of CTL precursors are seen for this epitope. It may nevertheless be possible to amplify this component by vaccination with the relevant peptide or with adoptive transfer of in vitro activated LMP1-specific CTLs. Such approaches may be of use in the control of HD and NPC.
- Efficient presentation of the YLLEMLWRL (SEQ ID NO: 1) peptide by HLA A*0201, HLA A*0203 and HLA A*0207-positive LCLs, which are common supertypes in the southeast Asian population, raises the possibility that this epitope might be exploited as a potential target epitope for LMP1-expressing NPC.
- Infectious Mononcleosis (IM) Patients
- IM patients, identified on clinical grounds and by heterophile antibody positivity, were bled during the first 5-10 days of illness and, in two cases, on a second occasion 24-36 months after the resolution of symptoms. These patients were HLA typed for the HLA A2 allele by serotyping in microcytotoxicity and by genotyping. Three patients (SB, LP and MG) were identified as HLA A2-positive patients and this was subsequently confirmed by FACS analysis using an HLA A2-specific monoclonal antibody (ATCC).
- Establishment and Maintenance of Cell Lines:
- EBV-transformed lymphoblastoid cell lines (LCLs) were established from a panel of IM and healthy EBV-seropositive donors by exogenous virus transformation of peripheral B cells using type 1 (B95.8) or type 2 (Ag876) EBV isolates (16), and were routinely maintained in RPMI 1640 containing 2 mM glutamine, 100 IU/ml penicillin and 100 ug/ml streptomycin plus 10% foetal calf serum (FCS) (growth medium). In addition, the peptide transporter (TAP)-negative B×T hybrid cell line 174×CEM.T2 (referred to as T2) (22) were used for peptide stablization assays.
- To generate phytohaemagglutinin (PHA) blasts peripheral blood mononuclear cells (PBMC) were stimulated with PHA (Commonwealth Serum Laboratories, Melbourne) and after 3 days, growth medium containing MLA 144 supernatant and rIL-2 was added (36). PHA blasts were propagated with bi-weekly replacement of IL-2 and MLA supernatant (no further PHA added) for up to 6 weeks.
- Establishment and Preparation of CTL Effectors
- Acute IM PBMC effectors for use in ex vivo cytotoxicity assays were resuspended in growth medium supplemented with recombinant IL2 and used directly in a cytotoxicity assay (see below). To generate polyclonal CTLs, PBMCs from HLA A2-positive donors were co-cultivated for seven days with irradiated (8,000 rads) T2 cells presensitized with synthetic peptides (37). On days 7 and 14, these cultures were restimulated with peptide-sensitized T2 cells. After 18 days of culture in growth medium, the cells were used as polyclonal effectors in a standard 51Cr-release assay against peptide-sensitized autologous PHA blasts.
- Synthesis of Peptides
- Peptides, synthesized by the Merrifield solid phase method, were purchased from Chiron Mimotopes (Melbourne, Australia), dissolved in dimethyl sulphoxide, and diluted in serum-free RPMI 1640 medium for use in standard CTL assays.
- MHC Stabilisation Assays
- HLA A2 binding peptides within the gp85 and gp350 antigens were identified using a protocol as described in Example 1. These predicted peptides were then used in a standard MHC stablization assay using T2 cells. Briefly, T2 cells (2×105) were incubated with 200 μl of each of the peptides (200 μg/ml) at 26° C. for 14-16 h, followed by incubation at 37° C. for 2-3 h. After the incubations. HLA A2 expression was measured by FACS using a monoclonal HLA A2-specific antibody (MA2.1: ATCC).
- Vaccinia Virus Recombinants
- Recombinant vaccinia constructs encoding the EBV structural antigens gp350 (Vacc.gp350) and gp85 (Vacc.gp85), and a vaccinia virus construct made by insertion of the pSC11 vector alone and negative for thymidine kinase (Vacc.TK−) have been previously described (38). Target cells were infected with recombinant vaccinia virus at a mutiplicity of infection (MOI) of 10:1 for 1 h at 37° C., as described earlier (6,12). After overnight infection, cells were washed with growth medium and processed for CTL assays or for immunoblotting to assess the expression of recombinant EBV antigens (11).
- Cytotoxicity Assay
- Target cells were either infected with recombinant vaccinia viruses or pre-sensitized with synthetic peptide epitopes and then incubated with 51Cr for 90 min. Following incubation, these cells were washed in growth medium and used as targets in a standard 5 h 51Cr-release assay (16).
- Immunisation of HLA A2/Kb Transgenic Mice with gp350 and gp85 CTL Epitopes
- HLA A2/K b transgenic mice used in this study have been described elsewhere (39). These mice express a chimeric class I molecule composed of the
alpha 1 & 2 domains of the human A*0201 allele and thealpha 3 domains of the mouse H-2Kb class I molecules. Peptide immunizations were carried out as described by Vitello and colleagues (40). Briefy, these animals were twice immunized (at a 14 day interval) subcutaneously with 50 ug/mouse of CTL epitopes emulsified in IFA together with 5 ug of Tetanus Toxoid as a source of help. Four weeks following peptide immunization, animals were assessed for gp350- and gp85-specific CTL response. For assessing these CTL responses, splenocytes (3×106 cells/ml) were cocultured with syngeneic, irradiated (2000 rad) peptide-coated LPS blasts (3×105 cells/ml) and 3 ug/ml human B2-microglobulin. CTL activity was tested onday 6 using a standard 51Cr-release assay. - Vaccinia Protection Assay
- For protection experiments, groups of 8 weeks old female A2/Kb transgenic mice were immunized with CTL epitopes as described above. On
day 28, mice were challenged with Vacc.gp85 and Vacc.gp350 intraperitonealy (1×107 pfu in 100 ul PBS). After four days of challenge, these animals were sacrificed and vaccinia titres measured in both ovaries by plaque assay on confluent CV1 cells. - Identification of HLA A2 Binding Peptides within gp85 and gp350
- To identify potential HLA A2-restricted epitopes within gp8S and gp350, the amino acid sequence was analyzed by a computer program designed to predict HLA-binding peptides, based on an estimation of the half-time disassociation of the HLA-peptide complex (http://bimas.dcrt.nih.gov/molbio/hla_bind/index.html) (18). A total of 20 peptides (13 from gp85 and 7 from gp350) with an estimated half-time disassociation score of >100 for gp85 and >50 for gp350 were selected (Table 3). These peptides were then tested for HLA A2 binding efficiency using HLA A2-positive T2 cells. Representative data from a series of experiments is presented in FIG. 8. This analysis showed that seven of these peptides significantly increased the expression of HLA A2 on T2 cells
TABLE 3 Identification of Potential HLA A2 Binding Peptides within gp85 and gp350* Score (Estimate half-time disassociation from HLA Ranking Residue Peptide Sequence A2 allele) gp85 peptides 1 177-185 FLMGTYKRV (SEQ ID NO:12) 1775.663 2 317-325 WLAKSFFEL (SEQ ID NO:13) 1082.903 3 672-680 GLYEERAHV (SEQ ID NO:14) 912.522 4 685-693 ILYFIAFAL (SEQ ID NO:15) 674.026 5 2-10 QLLCVFCLV (SEQ ID NO:16) 488.951 6 225-233 SLVIVTTFV (SEQ ID NO:17) 382.536 7 681-689 VLAIILYFI (SEQ ID NO:18) 224.537 8 684-692 IILYFIAFA (SEQ ID NO:19) 196.407 9 542-550 LMIIPLINV (SEQ ID NO:20) 181.738 10 1-9 MQLLCVFCL (SEQ ID NO:21) 181.738 11 7-15 FCLVLLWEV (SEQ ID NO:22) 133.298 12 658-666 YLLLTTNGT (SEQ ID NO:23) 126.883 13 420-428 TLFIGSHVV (SEQ ID NO:24) 105.510 gp350 peptides 1 871-879 VLTLLLLLV (SEQ ID NO:25) 271.948 2 152-160 LIPETVPYI (SEQ ID NO:26) 126.481 3 863-871 VLQWASLAV (SEQ ID NO:27) 118.238 4 875-883 LLLLVMADC (SEQ ID NO:28) 71.872 5 67-75 QLTPHTKAV (SEQ ID NO:29) 69.552 6 861-869 MLVLQWASL (SEQ ID NO:30) 61.737 7 873-881 TLLLLLVMA (SEQ ID NO:31) 42.278 - suggesting that these peptides might be potential HLA A2-restricted epitopes.
- Recognition of the gp85 and gp350 Peptide Epitopes by IM Effectors Ex Vivo
- The seven HLA A2-binding peptides, which included four peptides from gp85 and three peptides from gp350 were next tested for CTL recogniton by effectors from IM patients. In addition, we also included an HLA A2-restricted CTL epitope from EBV latent mambrane protein (LMP1) as a positive control (38). PBMCs from three HLA A2-positive IM patients, SB, LP and MG were resuspended in IL2-supplemented growth medium and used as effectors in a standard 51Cr-release assay against HLA-matched PHA blasts sensitized with the gp85, gp350 or LMP1 peptides. Representative data from two different experiments is shown in FIG. 9(A-C). Effectors from all three IM patients showed clear recognition of the reference LMP1 peptide (YLQQNWWTL (SEQ ID NO: 6)) consistent with our earlier finding that this peptide is recognized by EBV-specific CTLs. More importantly, these IM patients also showed strong recognition of target cells sensitized with selected gp85 or gp350 peptides. Interestingly, each of these individuals showed a distinct pattern of reactivity against these peptides. IM patient SB showed strong reactivity against peptides SLVIVTTFV (SEQ ID NO: 17) (gp85) and VLQWASLAV (SEQ ID NO: 27) (gp350) (FIG. 9A), while the LP and MG effectors recognised target cells preloaded with peptides LMIIPLINV (SEQ ID NO: 20) (gp85) and VLQWASIAV (SEQ ID NO: 27) (gp350) (FIG. 9(B-C)). Furthermore, ex vivo effectors from patient LP also recognised target cells infected with Vacc.gp350 and Vacc.gp85 (FIG. 9D).
- In Vitro Expansion of gp85 and gp350 Peptide Epitope Reactive CTLs
- The data presented above clearly demonstrate that gp85 and gp350 include CTL determinants which can bind HLA A2 molecules and are efficiently recognised by ex vivo effectors from IM patients. To determine whether gp85- or gp350-reactive CTLs can be detected following recovery from IM, PBMCs from the two donors SB and LP were collected at 24-36 months post IM respectively and were stimulated with T2 cells presensitized with each of the gp85 and gp350 peptides which showed strong HLA A2 binding. On day 18. these CTL effector were tested against peptide-sensitized autologous PHA blasts. Representative data from polyclonal CTLs from donor SB are presented in FIG. 10. CTL effectors from donor SB not only showed strong reactivity against peptides SLVIVTTFV (SEQ ID NO: 17) and VLQWASIAV (SEQ ID NO: 27) but also recognized two other peptides from gp85 (LMIIPLINV (SEQ ID NO: 20) and TLFIGSHVV (SEQ ID NO: 24)). Donor LP also showed a similar pattern of CTL lysis. Thus peptide TLFIGSHVV (SEQ ID NO: 24) was a target for EBV-specific CTL recogntion in the memory response of these A2-positive individuals, but this response was not detectable with ex vivo effectors during acute infection. Another important point which needs to be highlighted here is that our attempts to activate gp85- or gp350-specific CTLs with autologus LCLs as stimulators were unsuccessful. This result is not surprising since it is well established that in latently infected B cells, gp350 or gp85 antigens are poorly expressed. The LCL-stimulated polyclonal T cell lines from these donors strongly reactive against latent antigens (data not shown). This obseravtion is consistent with our earlier studies which showed that CTL responses in healthy virus carriers is often dominated by reactivity to latent antigens (6). Another explanation for an inability to detect gp350- or gp85-specific CTL reactivity following stimulation with the autologous LCLs is that these responses may constitute a minor component of the total virus specific CTL response in healthy virus carriers. Indeed, limiting dilution analysis for CTL precursors specific for the gp350 or gp85 peptide epitopes in post IM donors SB and LP showed precursor frequencies of >1/50,000, while precursor frequencies for CTLs that recognise CTL epitopes within the latent antigens were between 1/4,000-1/15,000 (data not shown).
- Immunization of HLA A2/Kb Mice with gp85 and gp350 Peptide Epitopes Induces Specific CTL Response
- Having established that gp85 and gp350 includes CTL epitopes, we extended our studies to explore the possibility of using these peptide epitopes to induce specific CTL response in vivo. HLA A2/Kb transgenic mice were used as an experimental model to address this issue. These mice express a chimeric class I molecule composed of the
alpha 1 & 2 domains of the human A*0201 allele and thealpha 3 domain of the mouse H-2Kb class I molecules. These animals were immunized subcutaneously with gp350 or gp85 CTL epitopes emulsified in IFA together with Tetanus Toxoid as a source of help. The SLVIVTTFV (SEQ ID NO: 17) and TLFIGSHVV (SEQ ID NO: 24) peptides from gp85 and the VLQWASLAV (SEQ ID NO: 27) peptide from gp350 were used for immunisation. Two weeks following immunization, specific CTL response was assessed in each mouse using splenocytes or pooled inguinal lymph node cells as effectors. Data presented in FIG. 11(A-C) demonstrate that peptide epitopes from gp85 (SLVIVTTFV (SEQ ID NO: 17) and TLFIGSHVV (SEQ ID NO: 24)) and gp350 (VLQWASLAV (SEQ ID NO: 27)) induced strong CTL response in splenocytes. Interestingly, CTLs activated from splenocytes with peptide TLFIGSHVV (SEQ ID NO: 24) consistently showed strong lysis of targets, while splenocytes from SLVIVTTFV (SEQ ID NO: 17) and VLQWASLAV (SEQ ID NO: 27) immunized mice showed variable in vitro CTL lysis. A strong specific CTL activity was also noticed in pooled lymphocytes from inguinal lymph nodes (FIG. 11D). - Prior Immunisation of HLA A2/Kb Mice with gp85 or gp350 CTL Epitopes Affords Protection Against Recombinant Vaccinia Virus Challenge
- Four weeks after peptide immunization with gp85 or gp350 CTL epitopes, HLA A2/K b mice were challenged with 107 pfu of recombinant vaccinia virus encoding either gp85 or gp350. After four days of challenge, these animals were sacrificed and vaccinia titres measured in both ovaries by plaque assay on confluent CV1 cells. Data from one such experiment is presented in FIG. 12. Animals immunised with gp85 and gp350 epitopes showed very low to undetectable virus in their ovaries, while in naive mice very high titres of vaccinia virus were detected. This protection correlated with strong induction of epitope-specific CTL responses detected in the splenocytes and lymph node cells collected four weeks after primary peptide vacciniation in HLA A2/Kb transgenic mice.
- There is increasing interest in formulating an effective vaccine against EBV, designed to not only limit the outgrowth of latently infected B cells in healthy individuals but to also block the development of many EBV-associated malignancies such as Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC) and Hodgkin's disease (HD). In western societies, the principle aim of such a vaccine would be to protect from IM. In this context, virus load (a large dose of orally transmitted virus and/or overexpansion of the virus-transformed B cell pool beyond a critical threshold) may be a critical determinant of disease risk (7). Therefore, a vaccine capable of either blocking primary EBV infection or significantly reducing the EBV load during primary infection may be adequate to avert clinical symptoms. A similar vaccine will also be able to reduce the immediate risk of lymphoproliferative disease in transplant patients receiving immunosuppressive therapy. On the other hand, EBV-associated malignancies such as BL, NPC, and HD arise in patients years after their primary infection, and protection from these longer-term consequences would require a vaccine that ideally confers sterile immunity and prevents the establishment of the carrier state.
- EBV structural antigens, primarily gp350, have long been considered as the potential candidates for an EBV vaccine. The suggestion that gp350 is a likely vaccine candidate was based initially upon the observation that this glycoprotein is the principal target of the virus-neutralizing antibody response (41). A number of recombinant formulations of gp350, either presented as a subunit antigen or expressed from recombinant viral vectors, designed to induce high titre neutralizing antibodies, have shown significant protection against EBV-induced B cell lymphomas in cotton-top tamarins (31). However, development of neutralizing antibodies in vaccinated animals does not always shows limited correlation with protection from EBV infection, although recent results have suggested a role for gp350-specific CTLs in this protection (34). If the latter suggestion is correct, it is important to identify the potential CTL determinants within EBV structural proteins since it is now well established that immunization with whole viral proteins is unable to elicit an efficient CTL response. Moreover, a vaccine based on CTL epitopes provides an opportunity to include determinants not only from gp350 but also from other structural antigens, such as gp85. To address this issue we have used a novel protocol to successfully identify CTL epitopes within gp350 and gp85. In the first set of experiments we identified HLA A2 binding peptides within gp350 and gp85. Subsequent experiments were focussed on IM patients with the HLA A2 allele. Using ex vivo primary effectors, we observed strong reactivity to three different gp350 and gp85 peptides. Interestingly, individual IM patients showed distinct patterns of reactivity to each of these peptides. Strong reactivity against peptides SLVIVTTFV (SEQ ID NO: 17) (gp85) and VLQWASLAV (SEQ ID NO: 27) (gp350) was observed with ex vivo effectors from patient SB, while the LP and MG effectors recognized target cells preloaded with LMIIPLINV (SEQ ID NO: 20) (gp85) and VLQWASLAV (SEQ ID NO: 27) (gp350) peptides. More importantly, ex vivo effectors from patient LP also recognised target cells infected with Vacc.gp350 and Vacc.gp85. Interestingly, the level of ex vivo CTL lysis directed to epitopes from structural antigens was consistently higher than those seen in the same assays against HLA A2-restricted CTL epitopes from a latent antigen. These results are consistent with recent observations by Steven and colleagues (42) that ex vivo CTL reactivity to lytic antigens in IM patients is significantly higher compared to latent antigens.
- In the next set of experiments, we explored the possibility of detecting structural antigen-specific CTL responses in individuals following resolution of IM symptoms. This follow up analysis was carried out 24-36 months post acute IM. Our initial attempts to isolate gp350- or gp85-specific CTLs from post IM donors by stimulating with the autologous LCL were unsuccessful. Subsequently we used peptide loaded T2 cells as stimulators to generate gp350- and gp85-specific CTLs. We have recently shown that this method can be successfully used to raise low frequency EBV-specific CTL precursors (38). Stimulation of PBMC from donors SB and LP raised strong CTL responses to the gp85 and gp350 CTL epitopes. Both donors SB and LP not only showed reactivity against peptides SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20) and VLQWASLAV (SEQ ID NO: 27) but also recognized another peptide from gp85, TLFIGSHVV (SEQ ID NO: 24). It is interesting to note here that both donors showed no ex vivo CTL reactivity to TLFIGSHVV (SEQ ID NO: 24) during acute IM. One of the important conclusions drawn from these analyses is that, following recovery from acute IM, there is a significant reduction in CTL precursors to the structural antigens, and the response becomes dominated by CTL reactive to the latent antigens. Indeed, limiting dilution analysis for CTL precursors specific for the gp350 or gp85 peptide epitopes in donors SB and LP post IM showed frequencies of >1/50,000, while precursor frequencies for CTL epitopes within latent antigens were between 1/4,000-1/15,000.
- The detection of a strong ex vivo CTL response in IM patients to the structural antigens has important implications for any future vaccine design. As mentioned above, to date, the major emphasis of vaccine design based on EBV structural antigens has been directed towards generating a strong neutralizing antibody response. However, these neutralising antibody response fail to correlate with protection against EBV-induced polyclonal lymphomas in cotton-top marmosets. Nevertheless, it is possible that this protection is mediated by structural antigen-specific CTL responses. To address this issue, we employed an experimental animal model system to determine whether gp350 or gp85 CTL epitope immunized transgenic mice, expressing the human HLA A2 antigen, are capable of (a) generating structural antigen-specific CTL responses and (b) reducing infection with a recombinant vaccinia virus infection expressing the gp350 or gp85 antigen. These mice not only showed induction of a strong CTL response following immunization but also acquired strong resistance to virus infection. It is important to mention here that although this experiment does not allow any firm conclusions on the efficacy of a gp350 and/or gp85 CTL epitope based vaccine in humans, it does clearly show that CTL epitopes from the EBV structural antigens can be used as immunogens to induce an efficient CTL response in vivo. Moreover, this approach also overcomes limitations of whole gp350 or gp85 proteins which might be inefficient at eliciting CTL responses in humans. Obviously one of the possible obstacles of any epitope-based approach to vaccination in humans is HLA polymorphism because epitope choice is allele-specific. However, this obstacle might be overcome using appropriate mixtures of synthetic peptide epitope or by constructing vectors to express polypeptides in which the relevant epitope sequences are linearly joined together. Indeed, earlier studies from our laboratory have shown that if such an EBV polyepitope sequence is expressed within cells from a recombinant vaccinia vector, all of the constituent epitopes are efficiently presented for CTL recognition (43), indicating the potential of this approach as a vaccine strategy. More recently, work in a murine model has also shown that each of several CTL epitopes combined in a polyepitope construct was capable of eliciting a CTL response in vivo and could protect the animals from subsequent challenge (44). In the long term, it may be possible to combine CTL epitopes from the EBV structural antigens with latent antigen epitopes generating a chimeric protein that fuses the important immunogenic determinants from the two different types of antigens to design an effective vaccine.
- It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
-
1 33 1 9 PRT Epstein Barr Virus 1 Tyr Leu Leu Glu Met Leu Trp Arg Leu 1 5 2 9 PRT Epstein Barr Virus 2 Leu Leu Leu Ala Leu Leu Phe Trp Leu 1 5 3 9 PRT Epstein Barr Virus 3 Leu Leu Val Asp Leu Leu Trp Leu Leu 1 5 4 9 PRT Epstein Barr Virus 4 Leu Leu Leu Ile Ala Leu Trp Asn Leu 1 5 5 9 PRT Epstein Barr Virus 5 Trp Leu Leu Leu Phe Leu Ala Ile Leu 1 5 6 9 PRT Epstein Barr Virus 6 Tyr Leu Gln Gln Asn Trp Trp Thr Leu 1 5 7 9 PRT Epstein Barr Virus 7 Thr Leu Leu Val Asp Leu Leu Trp Leu 1 5 8 9 PRT Epstein Barr Virus 8 Leu Leu Trp Leu Leu Leu Phe Leu Ala 1 5 9 9 PRT Epstein Barr Virus 9 Ile Leu Leu Ile Ile Ala Leu Tyr Leu 1 5 10 9 PRT Epstein Barr Virus 10 Val Leu Phe Ile Phe Gly Cys Leu Leu 1 5 11 9 PRT Epstein Barr Virus 11 Arg Leu Gly Ala Thr Ile Trp Gln Leu 1 5 12 9 PRT Epstein Barr Virus 12 Phe Leu Met Gly Thr Tyr Lys Arg Val 1 5 13 9 PRT Epstein Barr Virus 13 Trp Leu Ala Lys Ser Phe Phe Glu Leu 1 5 14 9 PRT Epstein Barr Virus 14 Gly Leu Tyr Glu Glu Arg Ala His Val 1 5 15 9 PRT Epstein Barr Virus 15 Ile Leu Tyr Phe Ile Ala Phe Ala Leu 1 5 16 9 PRT Epstein Barr Virus 16 Gln Leu Leu Cys Val Phe Cys Leu Val 1 5 17 9 PRT Epstein Barr Virus 17 Ser Leu Val Ile Val Thr Thr Phe Val 1 5 18 9 PRT Epstein Barr Virus 18 Val Leu Ala Ile Ile Leu Tyr Phe Ile 1 5 19 9 PRT Epstein Barr Virus 19 Ile Ile Leu Tyr Phe Ile Ala Phe Ala 1 5 20 9 PRT Epstein Barr Virus 20 Leu Met Ile Ile Pro Leu Ile Asn Val 1 5 21 9 PRT Epstein Barr Virus 21 Met Gln Leu Leu Cys Val Phe Cys Leu 1 5 22 9 PRT Epstein Barr Virus 22 Phe Cys Leu Val Leu Leu Trp Glu Val 1 5 23 9 PRT Epstein Barr Virus 23 Tyr Leu Leu Leu Thr Thr Asn Gly Thr 1 5 24 9 PRT Epstein Barr Virus 24 Thr Leu Phe Ile Gly Ser His Val Val 1 5 25 9 PRT Epstein Barr Virus 25 Val Leu Thr Leu Leu Leu Leu Leu Val 1 5 26 9 PRT Epstein Barr Virus 26 Leu Ile Pro Glu Thr Val Pro Tyr Ile 1 5 27 9 PRT Epstein Barr Virus 27 Val Leu Gln Trp Ala Ser Leu Ala Val 1 5 28 9 PRT Epstein Barr Virus 28 Leu Leu Leu Leu Val Met Ala Asp Cys 1 5 29 9 PRT Epstein Barr Virus 29 Gln Leu Thr Pro His Thr Lys Ala Val 1 5 30 9 PRT Epstein Barr Virus 30 Met Leu Val Leu Gln Trp Ala Ser Leu 1 5 31 9 PRT Epstein Barr Virus 31 Thr Leu Leu Leu Leu Leu Val Met Ala 1 5 32 9 PRT Epstein Barr Virus 32 Tyr Phe Leu Glu Ile Leu Trp Gly Leu 1 5 33 9 PRT Epstein Barr Virus 33 Tyr Leu Leu Glu Ile Leu Trp Arg Leu 1 5
Claims (32)
1. A cytotoxic Epstein-Barr virus (EBV) T-cell epitope the epitope being derived from an EBV structural antigen.
2. A cytotoxic EBV T-cell epitope as claimed in claim 1 wherein the EBV structural antigen is gp85 or gp350.
3. A cytotoxic T-cell epitope, the epitope being selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), YLQQNWWTL (SEQ ID NO: 6), LLLALLFWL (SEQ ID NO: 2), LLVDLLWLL (SEQ ID NO: 3), LLLIALWNL (SEQ ID NO: 4), WLLLFLAIL (SEQ ID NO: 5), TLLVDLLWL (SEQ ID NO: 7), LLWLLLFLA (SEQ ID NO: 8), ILLIIALYL (SEQ ID NO: 9), VLFIFGCLL (SEQ ID NO: 10), RLGATIWQL (SEQ ID NO: 11), ILYFIAFAL (SEQ ID NO: 15), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), LIPETVPYI (SEQ ID NO: 26), VLQWASLAV (SEQ ID NO: 27) and QLTPHTKAV (SEQ ID NO: 29).
4. A subunit vaccine including a cytotoxic Epstein-Barr virus (EBV) T-cell epitope as claimed in claim 1 or claim 2 .
5. A subunit vaccine including at least one T-cell epitope selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), YLQQNWWTL (SEQ ID NO: 6), LLLALLFWL (SEQ ID NO: 2), LLVDLLWLL (SEQ ID NO: 3), LLLIALWNL (SEQ ID NO: 4), WLLLFLAIL (SEQ ID NO: 5), TLLVDLLWL (SEQ ID NO: 7), LLWLLLFLA (SEQ ID NO: 8), ILLIIALYL (SEQ ID NO: 9), VLFIFGCLL (SEQ ID NO: 10), RLGATIWQL (SEQ ID NO: 11), ILYFIAFAL (SEQ ID NO: 15), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), LIPETVPYI (SEQ ID NO: 26), VLQWASLAV (SEQ ID NO: 27) and QLTPHTKAV (SEQ ID NO: 29).
6. A subunit vaccine as claimed in claim 5 wherein the epitope is selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YLQQNWWTL (SEQ ID NO: 6), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), and VLQWASLAV(SEQ ID NO: 27).
7. A subunit vaccine as claimed in any one of claims 4 to 6 wherein the vaccine further includes at least one antigen to which the individual will mount an anamnestic response in addition to the at least one cytotoxic T-cell epitope.
8. A subunit vaccine as claimed in claim 7 wherein the at least one antigen is selected from the group consisting of tetanus toxoid, diphtheria toxoid, Bordetella pertussis antigens, poliovirus antigens, purified protein derivative (PPD), gp350 protein, helper epitopes and combinations thereof.
9. A subunit vaccine as claimed in claim 8 wherein the at least one antigen is tetanus toxoid.
10. A subunit vaccine as claimed in any one of claims 4 to 9 in which the vaccine includes a water-in-oil formulation.
11. An isolated nucleic acid sequence encoding a cytotoxic Epstein-Barr virus (EBV) T-cell epitope as claimed in claim 1 or claim 2 .
12. An isolated nucleic acid sequence encoding at least one of the cytotoxic T-cell epitopes selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), YLQQNWWTL (SEQ ID NO: 6), LLLALLFWL (SEQ ID NO: 2), LLVDLLWLL (SEQ ID NO: 3), LLLIALWNL (SEQ ID NO: 4), WLLLFLAIL (SEQ ID NO: 5), TLLVDLLWL (SEQ ID NO: 7), LLWLLLFLA (SEQ ID NO: 8), ILLIIALYL (SEQ ID NO: 9), VLFIFGCLL (SEQ ID NO: 10), RLGATIWQL (SEQ ID NO: 11), ILYFIAFAL (SEQ ID NO: 15), SLVIVTTFV (SEQ ID NO: 17). LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), LIPETVPYI (SEQ ID NO: 26), VLQWASLAV (SEQ ID NO: 27) and QLTPHTKAV (SEQ ID NO: 29).
13. An isolated nucleic acid sequence as claimed in claim 12 wherein the epitope is selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YLQQNWWTL (SEQ ID NO: 6), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), and VLQWASLAV (SEQ ID NO: 27).
14. A vector including a nucleic acid sequence as claimed in any one of claims 11 to 13 .
15. A vector as claimed in claim 14 in which the vector is a bacteria, preferably Salmonella spp.
16. A vector as claimed in claim 14 in which the vector is a virus. preferably Adenovirus. Retrovirus or Vaccinia, and most preferably Modified Vaccinia Ankara.
17. An isolated polypeptide, the polypeptide including at least one EBV CTL epitope as claimed in any one of claims 1 to 3 .
18. A method of preparing a composition for use in inducing CTLs in a subject, the method including admixing at least one epitope as claimed in any one of claims 1 to 3 with at least one pharmaceutically acceptable carrier, diluent or excipient.
19. A method of reducing the risk of EBV infection in a subject which method includes administering to the subject an effective amount of:
(1) at least one CTL epitope as claimed in any one of claims 1 to 3 ;
(2) a subunit vaccine as claimed in any one of claims 4 to 10 ;
(3) a nucleic acid sequence as claimed in any one of claims 11 to 13 ;
(4) a vector as claimed in any one of claims 14 to 16 ; or
(5) a polypeptide as claimed in claim 17 .
20. A method of treating or preventing nasopharyngeal carcinoma or Hodgkin's disease in a subject which method includes administering to the subject an effective amount of at least one CTL epitope derived from an EBV structural or latent antigen.
21. A method according to claim 20 wherein the EBV structural antigen is gp85 or gp350.
22. A method according to claim 20 wherein the EBV latent antigen is LMP1 or LMP2.
23. A method according to claim 20 wherein at least one CTL epitope selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), YLQQNWWTL (SEQ ID NO: 6), LLLALLFWL (SEQ ID NO: 2), LLVDLLWLL(SEQ ID NO: 3), LLLIALWNL (SEQ ID NO: 4), WLLLFLAIL (SEQ ID NO: 5), TLLVDLLWL (SEQ ID NO. 7). LLWLLLFLA (SEQ ID NO: 8), ILLIIALYL (SEQ ID NO: 9), VLFIFGCLL (SEQ ID NO: 10), RLGATIWQL (SEQ ID NO: 11), ILYFIAFAL (SEQ ID NO: 15), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), LIPETVPYI (SEQ ID NO: 26), VLQWASIAV (SEQ ID NO: 27) and QLTPHTKAV (SEQ ID NO: 29), is administered to the subject.
24. A method of treating or preventing growth of NPC cells in a subject in need thereof which method includes administering to the subject at least one CTL epitope derived from an EBV structural or latent antigen.
25. A method according to claim 24 wherein the EBV structural antigen is gp85 or gp350.
26. A method according to claim 24 wherein the EBV latent antigen is LMP1 or LMP2.
27. A method according to claim 27 wherein at least one CTL epitope selected from the group consisting of YLLEMLWRL (SEQ ID NO: 1), YFLEILWGL (SEQ ID NO: 32), YLLEILWRL (SEQ ID NO: 33), YLQQNWWTL (SEQ ID NO: 6), LLLALLFWL (SEQ ID NO: 2), LLVDLLWLL (SEQ ID NO: 3), LLLIALWNL (SEQ ID NO: 4), WLLLFLAIL (SEQ ID NO: 5), TLLVDLLWL (SEQ ID NO: 7), LLWLLLFLA (SEQ ID NO: 8), ILLIIALYL (SEQ ID NO: 9), VLFIFGCLL (SEQ ID NO: 10), RLGATIWQL (SEQ ID NO: 11), ILYFIAFAL (SEQ ID NO: 15), SLVIVTTFV (SEQ ID NO: 17), LMIIPLINV (SEQ ID NO: 20), TLFIGSHVV (SEQ ID NO: 24), LIPETVPYI (SEQ ID NO: 26), VLQWASLAV (SEQ ID NO: 27) and QLTPHTKAV (SEQ ID NO: 29), is administered to the subject.
28. A method of treating or preventing the growth of NPC or HD cells in a first subject which method includes transferring to the first subject EBV-specific CTLs which recognise NPC or HD cells.
29. A method as claimed in claim 28 wherein the EBV-specific CTLs are obtained from the first subject by in vitro stimulation of CTLs by exposure to EBV CTL epitopes.
30. A method as claimed in claim 28 wherein the EBV-specific CTLs are obtained from a second subject, wherein the second subject is infected with EBV but does not have NPC or HD.
31. A method as claimed in claim 26 wherein the EBV-specific CTLs are LMP1 and/or LMP2-specific CTLs.
32. A method of reducing the risk of infectious mononucleosis or post transplantation lymphoproliferative disease in a subject which method includes administering to the subject an effective amount of:
(1) at least one CTL epitope as claimed in any one of claims 1 to 3 ;
(2) a subunit vaccine as claimed in any one of claims 4 to 10 ;
(3) a nucleic acid sequence as claimed in any one of claims 11 to 13 ;
(4) a vector as claimed in any one of claims 14 to 16 ; or
(5) a polypeptide as claimed in claim 17.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/356,829 US20030152582A1 (en) | 1997-07-10 | 2003-02-03 | CTL epitopes from EBV |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPO7841A AUPO784197A0 (en) | 1997-07-10 | 1997-07-10 | Treatment of nasopharyngeal carcinoma |
AUP07841 | 1997-07-10 | ||
US09/462,453 US6723695B1 (en) | 1997-07-10 | 1998-07-10 | CTL epitopes from EBV |
US10/356,829 US20030152582A1 (en) | 1997-07-10 | 2003-02-03 | CTL epitopes from EBV |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1998/000531 Division WO1999002550A1 (en) | 1997-07-10 | 1998-07-10 | Ctl epitopes from ebv |
US09/462,453 Division US6723695B1 (en) | 1997-07-10 | 1998-07-10 | CTL epitopes from EBV |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030152582A1 true US20030152582A1 (en) | 2003-08-14 |
Family
ID=3802132
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/462,453 Expired - Lifetime US6723695B1 (en) | 1997-07-10 | 1998-07-10 | CTL epitopes from EBV |
US10/356,829 Abandoned US20030152582A1 (en) | 1997-07-10 | 2003-02-03 | CTL epitopes from EBV |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/462,453 Expired - Lifetime US6723695B1 (en) | 1997-07-10 | 1998-07-10 | CTL epitopes from EBV |
Country Status (11)
Country | Link |
---|---|
US (2) | US6723695B1 (en) |
EP (1) | EP1003773B1 (en) |
JP (1) | JP2001509514A (en) |
CN (1) | CN100526331C (en) |
AT (1) | ATE418562T1 (en) |
AU (1) | AUPO784197A0 (en) |
CA (1) | CA2294732A1 (en) |
DE (1) | DE69840383D1 (en) |
NZ (1) | NZ501944A (en) |
WO (1) | WO1999002550A1 (en) |
ZA (1) | ZA986084B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101794304B1 (en) * | 2015-09-01 | 2017-11-06 | 가톨릭대학교 산학협력단 | EBV antigen specific T-cell receptor and use thereof |
WO2022084415A1 (en) | 2020-10-20 | 2022-04-28 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods and compositions for treating epstein barr virus-associated cancer |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1233781A1 (en) * | 1999-11-24 | 2002-08-28 | Oklahoma Medical Research Foundation | Assays and therapies for latent viral infection |
GB0210682D0 (en) * | 2002-05-09 | 2002-06-19 | Glaxosmithkline Biolog Sa | Novel use |
TW200416043A (en) * | 2002-11-07 | 2004-09-01 | Queensland Inst Med Res | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
US8067535B2 (en) | 2003-01-24 | 2011-11-29 | The University Of Massachusetts | Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes |
US7217526B2 (en) | 2003-01-24 | 2007-05-15 | University Of Massachusetts Medical School | Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes |
FR2850384A1 (en) * | 2003-01-28 | 2004-07-30 | Centre Nat Rech Scient | New antigen from intracellular pathogens, useful in vaccines against bacterial and viral infections, comprises sequences from extracellular domains of type III membrane proteins, also derived antibodies |
US8451808B2 (en) | 2006-02-18 | 2013-05-28 | Intel Corporation | Techniques for 40 megahertz (MHz) channel switching |
EP1826264A1 (en) * | 2006-02-24 | 2007-08-29 | Deutsches Primatenzentrum GmbH | Primate model for orthopox virus infections |
GB0706070D0 (en) * | 2007-03-28 | 2007-05-09 | Scancell Ltd | Nucleic acids |
SG10201407519TA (en) * | 2009-11-19 | 2015-01-29 | Univ Singapore | Method For Producing T Cell Receptor-Like Monoclonal Antibodies And Uses Thereof |
WO2012031132A1 (en) * | 2010-09-01 | 2012-03-08 | Baylor College Of Medicine | Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc) |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
BR112014014591A8 (en) | 2011-12-12 | 2017-07-04 | Baylor College Medicine | process for the in vitro expansion of antigen-specific t cells, expanded autologous or allogeneic t-cell product, pharmaceutical composition, and method of treatment of a patient, and uses of an engineered cell line, mixed pulsed dendritic cells antigen-peptide, t-apcs pulsed with antigen-peptide / peptide mixtures, and antigen-peptide mixtures with pbmcs |
PT2812431T (en) | 2012-02-09 | 2019-10-18 | Baylor College Medicine | Pepmixes to generate multiviral ctls with broad specificity |
JP2015516376A (en) * | 2012-03-19 | 2015-06-11 | ドイチェス クレブスフォルシュンクスツェントルム | B cell receptor complex binding protein comprising a T cell epitope |
JP2015533366A (en) | 2012-10-19 | 2015-11-24 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | Improved human herpesvirus immunotherapy |
US10576144B2 (en) | 2013-06-28 | 2020-03-03 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
EP3102590B1 (en) * | 2014-02-07 | 2019-08-07 | Valorisation-HSJ, Limited Partnership | Antigenic epitopes from ebv gp350/220 and uses thereof |
KR20160144455A (en) | 2014-04-15 | 2016-12-16 | 그리피스 유니버시티 | Group a streptococcus vaccine |
US11173205B2 (en) | 2014-11-05 | 2021-11-16 | Memorial Sloan Kettering Cancer Center | Methods of selecting T cell line and donor thereof for adoptive cellular therapy |
SG11201704962WA (en) | 2014-12-23 | 2017-07-28 | Margaret Anne Brimble | Amino acid and peptide conjugates and uses thereof |
EP3294304B1 (en) * | 2015-05-12 | 2020-01-29 | Memorial Sloan Kettering Cancer Center | Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy |
CN113791213A (en) | 2015-09-18 | 2021-12-14 | 贝勒医学院 | Identification of immunogenic antigens from pathogens and correlation with clinical efficacy |
JP6793746B2 (en) * | 2015-12-04 | 2020-12-02 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | Clinical correlation of immunotherapy efficacy |
CA3014515A1 (en) | 2016-02-26 | 2017-08-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
KR20190030661A (en) * | 2016-05-25 | 2019-03-22 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | How to treat autoimmune diseases using allogeneic T cells |
FI3507300T3 (en) | 2016-09-02 | 2023-04-03 | Univ James Cook | Wound healing peptide |
WO2018057823A1 (en) | 2016-09-23 | 2018-03-29 | Memorial Sloan Kettering Cancer Center | Generation and use in adoptive immunotherapy of stem cell-like memory t cells |
CN106397574A (en) * | 2016-10-21 | 2017-02-15 | 上海交通大学医学院附属新华医院 | Antigen epitope peptide and application thereof |
WO2018085888A1 (en) | 2016-11-09 | 2018-05-17 | Griffith University | Subtilase cytotoxin b subunit mutant |
CN107267481A (en) * | 2017-05-09 | 2017-10-20 | 上海交通大学医学院附属新华医院 | CDK5 epitope peptides and its application |
JP2021500360A (en) | 2017-10-23 | 2021-01-07 | アタラ バイオセラピューティクス,インコーポレーテッド | How to Manage Tumor Flare in Adoptive Immunotherapy |
NL2023863B1 (en) | 2019-09-20 | 2021-05-25 | Univ Griffith | Protein particles and uses thereof |
BR112022010167A2 (en) | 2019-11-25 | 2022-08-09 | Univ Griffith | IMMUNOGENIC PROTEIN AGAINST GONOCOCCAL INFECTION |
CN113621070A (en) | 2020-05-06 | 2021-11-09 | 华夏英泰(北京)生物技术有限公司 | T cell antigen receptor, polymer compound thereof, preparation method and application thereof |
MX2023004016A (en) * | 2020-10-07 | 2023-05-04 | Council Queensland Inst Medical Res | Herpesvirus polyepitope vaccines. |
CN115786509A (en) * | 2022-10-21 | 2023-03-14 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Nasopharynx cancer risk prediction kit |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3583564D1 (en) * | 1984-08-23 | 1991-08-29 | Hans Joachim Wolf | DNA SEQUENCES OF THE EBV GENOME, RECOMBINANT DNA MOLECULES, METHOD FOR THE PRODUCTION OF EBV-RELATED ANTIGENS, DIAGNOSTIC COMPOSITIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME ANTIGENS. |
US4879213A (en) * | 1986-12-05 | 1989-11-07 | Scripps Clinic And Research Foundation | Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse |
AU1648092A (en) | 1992-03-19 | 1993-10-21 | Cancer Research Campaign Technology Limited | Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins |
AU1942595A (en) * | 1994-03-16 | 1995-10-03 | Csl Limited | Cytotoxic t-cell epitopes |
AUPM446594A0 (en) | 1994-03-16 | 1994-04-14 | Csl Limited | Cytotoxic t-cell epitopes identified within epstein-barr virus |
MY114769A (en) * | 1994-04-18 | 2003-01-31 | Aviron Inc | Non-splicing variants of gp350/220 |
AU3072395A (en) * | 1994-07-27 | 1996-02-22 | Csl Limited | Polyepitope vaccines |
CA2195642A1 (en) * | 1994-07-27 | 1996-02-08 | Andreas Suhrbier | Polyepitope vaccines |
GB9501300D0 (en) * | 1995-01-24 | 1995-03-15 | Boughton Brian J | Peptides which inhibit viruses |
AUPO007396A0 (en) | 1996-05-24 | 1996-06-20 | Csl Limited | Ebv ctl epitopes |
AU712364B2 (en) * | 1996-05-24 | 1999-11-04 | Council Of The Queensland Institute Of Medical Research, The | EBV CTL epitopes |
-
1997
- 1997-07-10 AU AUPO7841A patent/AUPO784197A0/en not_active Abandoned
-
1998
- 1998-07-09 ZA ZA986084A patent/ZA986084B/en unknown
- 1998-07-10 CA CA002294732A patent/CA2294732A1/en not_active Abandoned
- 1998-07-10 WO PCT/AU1998/000531 patent/WO1999002550A1/en active IP Right Grant
- 1998-07-10 CN CNB98806992XA patent/CN100526331C/en not_active Expired - Lifetime
- 1998-07-10 DE DE69840383T patent/DE69840383D1/en not_active Expired - Fee Related
- 1998-07-10 NZ NZ501944A patent/NZ501944A/en unknown
- 1998-07-10 US US09/462,453 patent/US6723695B1/en not_active Expired - Lifetime
- 1998-07-10 JP JP2000502069A patent/JP2001509514A/en not_active Withdrawn
- 1998-07-10 EP EP98931834A patent/EP1003773B1/en not_active Expired - Lifetime
- 1998-07-10 AT AT98931834T patent/ATE418562T1/en not_active IP Right Cessation
-
2003
- 2003-02-03 US US10/356,829 patent/US20030152582A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101794304B1 (en) * | 2015-09-01 | 2017-11-06 | 가톨릭대학교 산학협력단 | EBV antigen specific T-cell receptor and use thereof |
US9993526B2 (en) | 2015-09-01 | 2018-06-12 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | EBV antigen specific T-cell receptor and use thereof |
US10251936B2 (en) | 2015-09-01 | 2019-04-09 | The Catholic Unviersity of Korea Industry-Academic Cooperation Foundation | EBV antigen specific T-cell receptor and use thereof |
WO2022084415A1 (en) | 2020-10-20 | 2022-04-28 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods and compositions for treating epstein barr virus-associated cancer |
Also Published As
Publication number | Publication date |
---|---|
EP1003773A1 (en) | 2000-05-31 |
NZ501944A (en) | 2001-11-30 |
WO1999002550A1 (en) | 1999-01-21 |
CA2294732A1 (en) | 1999-01-21 |
ZA986084B (en) | 1999-01-26 |
US6723695B1 (en) | 2004-04-20 |
EP1003773A4 (en) | 2002-08-07 |
AUPO784197A0 (en) | 1997-08-07 |
DE69840383D1 (en) | 2009-02-05 |
JP2001509514A (en) | 2001-07-24 |
EP1003773B1 (en) | 2008-12-24 |
WO1999002550A8 (en) | 2000-06-15 |
CN1269804A (en) | 2000-10-11 |
ATE418562T1 (en) | 2009-01-15 |
CN100526331C (en) | 2009-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6723695B1 (en) | CTL epitopes from EBV | |
US7976845B2 (en) | Human cytomegalovirus immunotherapy | |
JP4574166B2 (en) | Novel human cytomegalovirus (HCMV) cytotoxic T cell epitopes, polyepitopes, compositions containing them, and their diagnostic, prophylactic and therapeutic uses | |
Taylor et al. | Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+-and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma | |
AU2001249243B2 (en) | Immuno-reactive peptide CTL epitopes of human cytomegalovirus | |
Gönczöl et al. | Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate | |
EP1023319B1 (en) | Immuno-reactive peptide ctl epitopes of human cytomegalovirus | |
Khanna et al. | EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design | |
WO1994017810A1 (en) | Recombinant cytomegalovirus vaccine | |
WO1994023744A1 (en) | Recombinant cytomegalovirus vaccine | |
JP2569185B2 (en) | Synthetic antigen eliciting anti-HIV response | |
Tanaka et al. | Localization of an immunorecessive epitope on SV40 T antigen by H-2Db-restricted cytotoxic T-lymphocyte clones and a synthetic peptide | |
KR100905264B1 (en) | T helper cell epitopes | |
CA2271784A1 (en) | Immuno-reactive peptide ctl epitopes of human cytomegalovirus | |
EP0906335A1 (en) | Ebv ctl epitopes | |
US6699477B2 (en) | EBV CTL epitopes | |
AU756081B2 (en) | CTL epitopes from EBV | |
Taylor | T cell-based therapies for EBV-associated malignancies | |
AU2012227280B2 (en) | Human cytomegalovirus immunotherapy | |
EP1612217A2 (en) | Immuno-reactive peptide CTL epitopes of human cytomegalovirus | |
AU712364B2 (en) | EBV CTL epitopes | |
AU2005309341A1 (en) | Human cytomegalovirus immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |